e10vq
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
|
|
|
þ |
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended Feb. 28, 2010
or
|
|
|
o |
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _________ to _________
Commission file number 001-16167
MONSANTO COMPANY
(Exact name of registrant as specified in its charter)
|
|
|
Delaware
(State or other jurisdiction of incorporation or organization)
|
|
43-1878297
(I.R.S. Employer Identification No.) |
|
|
|
800 North Lindbergh Blvd.,
St. Louis, MO
(Address of principal executive offices)
|
|
63167
(Zip Code) |
(314) 694-1000
(Registrants telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports required to be
filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months
(or for such shorter period that the registrant was required to file such reports), and (2) has
been subject to such filing requirements for the past 90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted electronically and posted on its
corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T
(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes þ No o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated
filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large
accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the
Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer þ
|
|
Accelerated filer o
|
|
Non-accelerated filer o
|
|
Smaller reporting company o |
|
|
(Do not check if a smaller reporting company)
|
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of
the Exchange Act). Yes o No þ
Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date: 545,557,688 shares of Common Stock, $0.01 par value, outstanding as
of April 1, 2010.
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
CAUTION REGARDING FORWARD-LOOKING STATEMENTS
In the interests of our investors, and in accordance with the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995, this section of our report explains some of the
important reasons that actual results may be materially different from those that we anticipate. In
this report, and from time to time throughout the year, we share our expectations for our companys
future performance. These forward-looking statements include statements about our business plans;
the potential development, regulatory approval, and public acceptance of our products; our expected
financial performance, including sales performance, and the anticipated effect of our strategic
actions; the anticipated benefits of recent acquisitions; the outcome of contingencies, such as
litigation; domestic or international economic, political and market conditions; and other factors
that could affect our future results of operations or financial position, including, without
limitation, statements under the captions Overview Executive Summary Outlook, Seeds and
Genomics Segment, Agricultural Productivity Segment, Financial Condition, Liquidity, and
Capital Resources, Outlook, Critical Accounting Policies and Estimates and Legal
Proceedings. Any statements we make that are not matters of current reportage or historical fact
should be considered forward-looking. Such statements often include words such as believe,
expect, anticipate, intend, plan, estimate, will, and similar expressions. By their
nature, these types of statements are uncertain and are not guarantees of our future performance.
Since these statements are based on factors that involve risks and uncertainties, our companys
actual performance and results may differ materially from those described or implied by such
forward-looking statements. Factors that could cause or contribute to such differences include,
among others: continued competition in seeds, traits and agricultural chemicals; the companys
exposure to various contingencies, including those related to intellectual property protection,
regulatory compliance and the speed with which approvals are received, and public acceptance of
biotechnology products; the success of the companys research and development activities; the
outcomes of major lawsuits; developments related to foreign currencies and economies; successful
operation of recent acquisitions; fluctuations in commodity prices; compliance with regulations
affecting our manufacturing; the accuracy of the companys estimates related to distribution
inventory levels; the companys ability to fund its short-term financing needs and to obtain
payment for the products that it sells; the effect of weather conditions, natural disasters and
accidents on the agriculture business or the companys facilities; and other risks and factors
described or referenced in Part II Item 1A Risk Factors below and Part I Item 1A of our
Report on Form 10-K for the fiscal year ended Aug. 31, 2009.
Our forward-looking statements represent our estimates and expectations and are based on currently
available information at the time that we make those statements. However, circumstances change
constantly, often unpredictably, and many events beyond our control will determine whether the
expectations encompassed in our forward-looking statements will be realized. As a result, investors
should not place undue reliance on these forward-looking statements. We disclaim any current
intention or obligation to revise or update any forward-looking statements, or the factors that may
affect their realization, whether in light of new information, future events or otherwise, and
investors should not rely on us to do so.
1
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
TABLE OF CONTENTS
|
|
|
|
|
|
|
PART IFINANCIAL INFORMATION |
|
Page |
|
Item 1. |
|
Financial Statements |
|
|
3 |
|
|
|
Statements of Consolidated Operations |
|
|
4 |
|
|
|
Condensed Statements of Consolidated Financial Position |
|
|
5 |
|
|
|
Statements of Consolidated Cash Flows |
|
|
6 |
|
|
|
Condensed Statements of Consolidated Shareowners Equity
and Comprehensive Income |
|
|
7 |
|
|
|
Notes to Consolidated Financial Statements |
|
|
8 |
|
Item 2. |
|
Managements Discussion and Analysis of Financial
Condition and Results of Operations |
|
|
32 |
|
|
|
Overview |
|
|
32 |
|
|
|
Results of Operations Second Quarter Fiscal Year 2010 |
|
|
34 |
|
|
|
Seeds and Genomics Segment |
|
|
37 |
|
|
|
Agricultural Productivity Segment |
|
|
38 |
|
|
|
Restructuring |
|
|
39 |
|
|
|
Financial Condition, Liquidity, and Capital Resources |
|
|
41 |
|
|
|
Outlook |
|
|
46 |
|
|
|
Critical Accounting Policies and Estimates |
|
|
49 |
|
|
|
New Accounting Standards |
|
|
50 |
|
Item 3. |
|
Quantitative and Qualitative Disclosures About Market Risk |
|
|
51 |
|
Item 4. |
|
Controls and Procedures |
|
|
51 |
|
|
|
|
|
|
|
|
PART IIOTHER INFORMATION |
|
Item 1. |
|
Legal Proceedings |
|
|
52 |
|
Item 1A. |
|
Risk Factors |
|
|
53 |
|
Item 2. |
|
Unregistered Sales of Equity Securities and Use of Proceeds |
|
|
54 |
|
Item 5. |
|
Other Information |
|
|
55 |
|
Item 6. |
|
Exhibits |
|
|
55 |
|
SIGNATURE |
|
|
56 |
|
EXHIBIT INDEX |
|
|
57 |
|
2
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
PART IFINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
The Statements of Consolidated Operations of Monsanto Company and its consolidated subsidiaries for
the three months and six months ended Feb. 28, 2010, and Feb. 28, 2009, the Condensed Statements of
Consolidated Financial Position as of Feb. 28, 2010, and Aug. 31, 2009, the Statements of
Consolidated Cash Flows for the six months ended Feb. 28, 2010, and Feb. 28, 2009, the Condensed
Statements of Consolidated Shareowners Equity and Comprehensive Income for the six months ended
Feb. 28, 2010, and year ended Aug. 31, 2009, and related Notes to Consolidated Financial Statements
follow. Unless otherwise indicated, Monsanto and the company are used interchangeably to refer
to Monsanto Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the
context. Unless otherwise indicated, earnings (loss) per share and per share mean diluted
earnings (loss) per share. In the notes to the consolidated financial statements, all dollars are
expressed in millions, except per share amounts. Unless otherwise indicated, trademarks owned or
licensed by Monsanto or its subsidiaries are shown in all capital letters. Unless otherwise
indicated, references to ROUNDUP herbicides mean ROUNDUP branded herbicides, excluding all
lawn-and-garden herbicides, and references to ROUNDUP and other glyphosate-based herbicides
exclude all lawn-and-garden herbicides.
3
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
Statements of Consolidated Operations
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions, except per share amounts) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net Sales |
|
$ |
3,890 |
|
|
$ |
4,035 |
|
|
$ |
5,587 |
|
|
$ |
6,684 |
|
Cost of goods sold |
|
|
1,791 |
|
|
|
1,514 |
|
|
|
2,749 |
|
|
|
2,613 |
|
|
|
|
Gross Profit |
|
|
2,099 |
|
|
|
2,521 |
|
|
|
2,838 |
|
|
|
4,071 |
|
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
512 |
|
|
|
522 |
|
|
|
1,008 |
|
|
|
1,072 |
|
Research and development expenses |
|
|
279 |
|
|
|
265 |
|
|
|
546 |
|
|
|
517 |
|
Acquired in-process research and development |
|
|
|
|
|
|
162 |
|
|
|
|
|
|
|
162 |
|
Restructuring charges, net |
|
|
30 |
|
|
|
|
|
|
|
44 |
|
|
|
|
|
|
|
|
Total Operating Expenses |
|
|
821 |
|
|
|
949 |
|
|
|
1,598 |
|
|
|
1,751 |
|
Income from Operations |
|
|
1,278 |
|
|
|
1,572 |
|
|
|
1,240 |
|
|
|
2,320 |
|
Interest expense |
|
|
41 |
|
|
|
26 |
|
|
|
80 |
|
|
|
49 |
|
Interest income |
|
|
(14 |
) |
|
|
(18 |
) |
|
|
(25 |
) |
|
|
(43 |
) |
Other expense (income), net |
|
|
2 |
|
|
|
32 |
|
|
|
(10 |
) |
|
|
58 |
|
|
|
|
Income from Continuing Operations Before Income Taxes |
|
|
1,249 |
|
|
|
1,532 |
|
|
|
1,195 |
|
|
|
2,256 |
|
Income tax provision |
|
|
360 |
|
|
|
440 |
|
|
|
330 |
|
|
|
616 |
|
|
|
|
Income from Continuing Operations Including Portion
Attributable to Noncontrolling Interest |
|
$ |
889 |
|
|
$ |
1,092 |
|
|
$ |
865 |
|
|
$ |
1,640 |
|
|
|
|
Discontinued Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations of discontinued businesses |
|
|
|
|
|
|
1 |
|
|
|
5 |
|
|
|
19 |
|
Income tax provision |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8 |
|
|
|
|
Income on Discontinued Operations |
|
|
|
|
|
|
1 |
|
|
|
5 |
|
|
|
11 |
|
|
|
|
Net Income |
|
$ |
889 |
|
|
$ |
1,093 |
|
|
$ |
870 |
|
|
$ |
1,651 |
|
|
|
|
Less: Net income attributable to noncontrolling interest |
|
|
2 |
|
|
|
1 |
|
|
|
2 |
|
|
|
3 |
|
|
|
|
Net Income Attributable to Monsanto Company |
|
$ |
887 |
|
|
$ |
1,092 |
|
|
$ |
868 |
|
|
$ |
1,648 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amounts Attributable to Monsanto Company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
887 |
|
|
$ |
1,091 |
|
|
$ |
863 |
|
|
$ |
1,637 |
|
Income on discontinued operations |
|
|
|
|
|
|
1 |
|
|
|
5 |
|
|
|
11 |
|
|
|
|
Net Income Attributable to Monsanto Company |
|
$ |
887 |
|
|
$ |
1,092 |
|
|
$ |
868 |
|
|
$ |
1,648 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic Earnings per Share Attributable to Monsanto Company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
1.63 |
|
|
$ |
1.99 |
|
|
$ |
1.58 |
|
|
$ |
2.99 |
|
Income on discontinued operations |
|
|
|
|
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.02 |
|
|
|
|
Net Income |
|
$ |
1.63 |
|
|
$ |
2.00 |
|
|
$ |
1.59 |
|
|
$ |
3.01 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted Earnings per Share Attributable to Monsanto Company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
1.60 |
|
|
$ |
1.96 |
|
|
$ |
1.56 |
|
|
$ |
2.94 |
|
Income on discontinued operations |
|
|
|
|
|
|
0.01 |
|
|
|
0.01 |
|
|
|
0.02 |
|
|
|
|
Net Income |
|
$ |
1.60 |
|
|
$ |
1.97 |
|
|
$ |
1.57 |
|
|
$ |
2.96 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average Shares Outstanding: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic |
|
|
545.8 |
|
|
|
547.2 |
|
|
|
545.7 |
|
|
|
548.0 |
|
Diluted |
|
|
553.4 |
|
|
|
555.5 |
|
|
|
553.4 |
|
|
|
556.5 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dividends Declared per Share |
|
$ |
0.53 |
|
|
$ |
0.51 |
|
|
$ |
0.53 |
|
|
$ |
0.51 |
|
The accompanying notes are an integral part of these consolidated financial statements.
4
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
Condensed Statements of Consolidated Financial Position
|
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
As of Feb. 28, |
|
|
As of Aug. 31, |
|
(Dollars in millions, except share amounts) |
|
2010 |
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Assets |
|
|
|
|
|
|
|
|
Current Assets: |
|
|
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
1,607 |
|
|
$ |
1,956 |
|
Trade receivables, net |
|
|
2,093 |
|
|
|
1,556 |
|
Miscellaneous receivables |
|
|
634 |
|
|
|
654 |
|
Deferred tax assets |
|
|
595 |
|
|
|
662 |
|
Inventory, net |
|
|
3,199 |
|
|
|
2,934 |
|
Other current assets |
|
|
117 |
|
|
|
121 |
|
|
|
|
|
Total Current Assets |
|
|
8,245 |
|
|
|
7,883 |
|
Total property, plant and equipment |
|
|
7,391 |
|
|
|
7,158 |
|
Less accumulated depreciation |
|
|
3,704 |
|
|
|
3,549 |
|
|
|
|
|
Property, Plant and Equipment, Net |
|
|
3,687 |
|
|
|
3,609 |
|
Goodwill |
|
|
3,226 |
|
|
|
3,218 |
|
Other Intangible Assets, Net |
|
|
1,313 |
|
|
|
1,371 |
|
Noncurrent Deferred Tax Assets |
|
|
775 |
|
|
|
743 |
|
Long-Term Receivables, Net |
|
|
468 |
|
|
|
557 |
|
Other Assets |
|
|
532 |
|
|
|
496 |
|
|
|
|
|
Total Assets |
|
$ |
18,246 |
|
|
$ |
17,877 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Shareowners Equity |
|
|
|
|
|
|
|
|
Current Liabilities: |
|
|
|
|
|
|
|
|
Short-term debt, including current portion of long-term debt |
|
$ |
114 |
|
|
$ |
79 |
|
Accounts payable |
|
|
673 |
|
|
|
676 |
|
Income taxes payable |
|
|
266 |
|
|
|
79 |
|
Accrued compensation and benefits |
|
|
185 |
|
|
|
263 |
|
Accrued marketing programs |
|
|
667 |
|
|
|
934 |
|
Deferred revenues |
|
|
601 |
|
|
|
219 |
|
Grower production accruals |
|
|
208 |
|
|
|
139 |
|
Dividends payable |
|
|
145 |
|
|
|
145 |
|
Customer payable |
|
|
|
|
|
|
307 |
|
Restructuring reserves |
|
|
197 |
|
|
|
286 |
|
Miscellaneous short-term accruals |
|
|
623 |
|
|
|
629 |
|
|
|
|
|
Total Current Liabilities |
|
|
3,679 |
|
|
|
3,756 |
|
Long-Term Debt |
|
|
1,726 |
|
|
|
1,724 |
|
Postretirement Liabilities |
|
|
720 |
|
|
|
793 |
|
Long-Term Deferred Revenue |
|
|
444 |
|
|
|
488 |
|
Noncurrent Deferred Tax Liabilities |
|
|
140 |
|
|
|
153 |
|
Long-Term Portion of Environmental and Litigation Liabilities |
|
|
191 |
|
|
|
197 |
|
Other Liabilities |
|
|
605 |
|
|
|
641 |
|
Shareowners Equity: |
|
|
|
|
|
|
|
|
Common stock (authorized: 1,500,000,000 shares, par value $0.01) |
|
|
|
|
|
|
|
|
Issued 587,322,226 and 585,557,964 shares, respectively |
|
|
|
|
|
|
|
|
Outstanding 545,569,237 and 545,407,427 shares, respectively |
|
|
6 |
|
|
|
6 |
|
Treasury stock 41,752,989 and 40,150,537 shares, respectively, at cost |
|
|
(1,701 |
) |
|
|
(1,577 |
) |
Additional contributed capital |
|
|
9,815 |
|
|
|
9,695 |
|
Retained earnings |
|
|
3,260 |
|
|
|
2,682 |
|
Accumulated other comprehensive loss |
|
|
(674 |
) |
|
|
(744 |
) |
Reserve for ESOP debt retirement |
|
|
(5 |
) |
|
|
(6 |
) |
|
|
|
|
Total Monsanto Company Shareowners Equity |
|
|
10,701 |
|
|
|
10,056 |
|
|
|
|
|
Noncontrolling Interest |
|
|
40 |
|
|
|
69 |
|
|
|
|
|
Total Shareowners Equity |
|
|
10,741 |
|
|
|
10,125 |
|
|
|
|
|
Total Liabilities and Shareowners Equity |
|
$ |
18,246 |
|
|
$ |
17,877 |
|
|
|
|
|
The accompanying notes are an integral part of these consolidated financial statements.
5
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
Statements of Consolidated Cash Flows
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
|
|
|
|
|
|
|
|
|
Operating Activities: |
|
|
|
|
|
|
|
|
Net Income |
|
$ |
870 |
|
|
$ |
1,651 |
|
Adjustments to reconcile cash provided by operating activities: |
|
|
|
|
|
|
|
|
Items that did not require (provide) cash: |
|
|
|
|
|
|
|
|
Depreciation and amortization |
|
|
294 |
|
|
|
270 |
|
Bad-debt expense |
|
|
26 |
|
|
|
49 |
|
Stock-based compensation expense |
|
|
52 |
|
|
|
55 |
|
Excess tax benefits from stock-based compensation |
|
|
(31 |
) |
|
|
(12 |
) |
Deferred income taxes |
|
|
(62 |
) |
|
|
2 |
|
Restructuring charges, net |
|
|
44 |
|
|
|
|
|
Equity affiliate income, net |
|
|
(18 |
) |
|
|
(9 |
) |
Acquired in-process research and development |
|
|
|
|
|
|
162 |
|
Net gain on sales of a business or other assets |
|
|
(2 |
) |
|
|
(6 |
) |
Other items |
|
|
38 |
|
|
|
(2 |
) |
Changes in assets and liabilities that provided (required) cash, net of acquisitions: |
|
|
|
|
|
|
|
|
Trade receivables, net |
|
|
(459 |
) |
|
|
(244 |
) |
Inventory, net |
|
|
(241 |
) |
|
|
(972 |
) |
Deferred revenues |
|
|
341 |
|
|
|
158 |
|
Accounts payable and other accrued liabilities |
|
|
(323 |
) |
|
|
402 |
|
Restructuring cash payments |
|
|
(124 |
) |
|
|
|
|
Pension contributions |
|
|
(86 |
) |
|
|
(34 |
) |
Net investment hedge settlement |
|
|
(4 |
) |
|
|
27 |
|
Other items |
|
|
(59 |
) |
|
|
3 |
|
|
Net Cash Provided by Operating Activities |
|
|
256 |
|
|
|
1,500 |
|
|
Cash Flows Required by Investing Activities: |
|
|
|
|
|
|
|
|
Maturities of short-term investments |
|
|
|
|
|
|
102 |
|
Capital expenditures |
|
|
(342 |
) |
|
|
(461 |
) |
Acquisition of businesses, net of cash acquired |
|
|
(23 |
) |
|
|
(273 |
) |
Purchases of long-term debt and equity securities |
|
|
(8 |
) |
|
|
(7 |
) |
Technology and other investments |
|
|
(14 |
) |
|
|
(26 |
) |
Proceeds from divestiture of a business |
|
|
|
|
|
|
300 |
|
Other investments and property disposal proceeds |
|
|
42 |
|
|
|
6 |
|
|
Net Cash Required by Investing Activities |
|
|
(345 |
) |
|
|
(359 |
) |
|
Cash Flows Required by Financing Activities: |
|
|
|
|
|
|
|
|
Net change in financing with less than 90-day maturities |
|
|
126 |
|
|
|
(73 |
) |
Short-term debt proceeds |
|
|
25 |
|
|
|
55 |
|
Short-term debt reductions |
|
|
(32 |
) |
|
|
|
|
Long-term debt reductions |
|
|
(1 |
) |
|
|
(69 |
) |
Payments on other financing |
|
|
(1 |
) |
|
|
|
|
Treasury stock purchases |
|
|
(124 |
) |
|
|
(274 |
) |
Stock option exercises |
|
|
38 |
|
|
|
17 |
|
Excess tax benefits from stock-based compensation |
|
|
31 |
|
|
|
12 |
|
Dividend payments |
|
|
(290 |
) |
|
|
(264 |
) |
Dividend payments to noncontrolling interests |
|
|
(31 |
) |
|
|
(5 |
) |
|
Net Cash Required by Financing Activities |
|
|
(259 |
) |
|
|
(601 |
) |
|
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
|
|
(1 |
) |
|
|
(149 |
) |
|
Net (Decrease) Increase in Cash and Cash Equivalents |
|
|
(349 |
) |
|
|
391 |
|
Cash and Cash Equivalents at Beginning of Period |
|
|
1,956 |
|
|
|
1,613 |
|
|
Cash and Cash Equivalents at End of Period |
|
$ |
1,607 |
|
|
$ |
2,004 |
|
|
See Note 19 Supplemental Cash Flow Information for further details.
The accompanying notes are an integral part of these consolidated financial statements.
6
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
Condensed Statements of Consolidated Shareowners Equity and Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Monsanto Shareowners |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated |
|
|
|
|
|
|
|
|
|
|
Unaudited |
|
|
|
|
|
|
|
|
|
Additional |
|
|
|
|
|
|
Other |
|
|
Reserve |
|
|
Non- |
|
|
|
|
(Dollars in millions, |
|
Common |
|
|
Treasury |
|
|
Contributed |
|
|
Retained |
|
|
Comprehensive |
|
|
for ESOP |
|
|
Controlling |
|
|
|
|
except per share amounts) |
|
Stock |
|
|
Stock |
|
|
Capital |
|
|
Earnings |
|
|
(Loss)(1) |
|
|
Debt |
|
|
Interests |
|
|
Total |
|
|
Balance as of Aug. 31, 2008 |
|
$ |
6 |
|
|
$ |
(1,177 |
) |
|
$ |
9,495 |
|
|
$ |
1,138 |
|
|
$ |
(78 |
) |
|
$ |
(10 |
) |
|
$ |
37 |
|
|
$ |
9,411 |
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,109 |
|
|
|
|
|
|
|
|
|
|
|
24 |
|
|
|
2,133 |
|
Foreign currency translation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(333 |
) |
|
|
|
|
|
|
(5 |
) |
|
|
(338 |
) |
Postretirement benefit plan activity,
net of tax of $(119) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(189 |
) |
|
|
|
|
|
|
|
|
|
|
(189 |
) |
Accumulated derivative activity,
net of tax of $(95) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(144 |
) |
|
|
|
|
|
|
|
|
|
|
(144 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income for 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
19 |
|
|
|
1,462 |
|
Treasury stock purchases |
|
|
|
|
|
|
(400 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(400 |
) |
Restricted stock withholding |
|
|
|
|
|
|
|
|
|
|
(7 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7 |
) |
Issuance of shares under
employee stock plans |
|
|
|
|
|
|
|
|
|
|
39 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
39 |
|
Excess tax benefits from stock-
based compensation |
|
|
|
|
|
|
|
|
|
|
35 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
35 |
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
133 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
133 |
|
Cash dividends of $1.04 per
common share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(565 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(565 |
) |
Dividend payments to
noncontrolling interests |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(10 |
) |
|
|
(10 |
) |
Allocation of ESOP shares,
net of dividends received |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
4 |
|
Donation of noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28 |
|
|
|
28 |
|
Purchase of noncontrolling interest |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(5 |
) |
|
|
(5 |
) |
|
Balance as of Aug. 31, 2009 |
|
$ |
6 |
|
|
$ |
(1,577 |
) |
|
$ |
9,695 |
|
|
$ |
2,682 |
|
|
$ |
(744 |
) |
|
$ |
(6 |
) |
|
$ |
69 |
|
|
$ |
10,125 |
|
Net income |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
868 |
|
|
|
|
|
|
|
|
|
|
|
2 |
|
|
|
870 |
|
Foreign currency translation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(17 |
) |
|
|
|
|
|
|
|
|
|
|
(17 |
) |
Postretirement benefit plan activity,
net of tax of $14 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
22 |
|
|
|
|
|
|
|
|
|
|
|
22 |
|
Realized and unrealized gain on
investments, net of tax of $2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
3 |
|
Accumulated derivative activity,
net of tax of $37 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
62 |
|
|
|
|
|
|
|
|
|
|
|
62 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comprehensive income for six
months ended Feb. 28, 2010 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2 |
|
|
|
940 |
|
Treasury stock purchases |
|
|
|
|
|
|
(124 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(124 |
) |
Restricted stock withholding |
|
|
|
|
|
|
|
|
|
|
(1 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1 |
) |
Issuance of shares under
employee stock plans |
|
|
|
|
|
|
|
|
|
|
38 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
38 |
|
Excess tax benefits from stock-
based compensation |
|
|
|
|
|
|
|
|
|
|
31 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31 |
|
Stock-based compensation expense |
|
|
|
|
|
|
|
|
|
|
52 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
52 |
|
Cash dividends of $0.53 per
common share |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(290 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(290 |
) |
Dividend payments to
noncontrolling interests |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(31 |
) |
|
|
(31 |
) |
Allocation of ESOP shares,
net of dividends received |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
1 |
|
|
Balance as of Feb. 28, 2010 |
|
$ |
6 |
|
|
$ |
(1,701 |
) |
|
$ |
9,815 |
|
|
$ |
3,260 |
|
|
$ |
(674 |
) |
|
$ |
(5 |
) |
|
$ |
40 |
|
|
$ |
10,741 |
|
|
|
|
|
(1) |
|
See Note 17 Comprehensive Income (Loss) for further details of the components of accumulated other comprehensive loss. |
The accompanying notes are an integral part of these consolidated financial statements.
7
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
NOTE 1. BACKGROUND AND BASIS OF PRESENTATION
Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural
products for farmers. Monsantos seeds, biotechnology trait products, and herbicides provide
farmers with solutions that improve productivity, reduce the costs of farming and produce better
foods for consumers and better feed for animals.
Monsanto manages its business in two segments: Seeds and Genomics and Agricultural Productivity.
Through the Seeds and Genomics segment, Monsanto produces leading seed brands, including DEKALB,
ASGROW, DELTAPINE, SEMINIS and DE RUITER, and Monsanto develops biotechnology traits that assist
farmers in controlling insects and weeds. Monsanto also provides other seed companies with genetic
material and biotechnology traits for their seed brands. Through the Agricultural Productivity
segment, the company manufactures ROUNDUP brand herbicides and other herbicides and provides
lawn-and-garden herbicide products for the residential market. See Note 21 Segment Information
for further details.
In the fourth quarter of 2008, the company announced plans to divest its animal agricultural
products business, which focused on dairy cow productivity (the Dairy business). This transaction
was consummated on Oct. 1, 2008. As a result, financial data for this business has been presented
as discontinued operations. The financial statements have been prepared in compliance with the
provisions of the Property, Plant and Equipment topic of the Financial Accounting Standards Board
(FASB) Accounting Standards Codification (ASC). Accordingly, for all periods presented herein, the
Statements of Consolidated Operations have been conformed to this presentation. See Note 22
Discontinued Operations for further details.
The accompanying consolidated financial statements have not been audited but have been prepared in
conformity with accounting principles generally accepted in the United States for interim financial
information and with instructions to Form 10-Q and Article 10 of Regulation S-X. In the opinion of
management, these unaudited consolidated financial statements contain all adjustments necessary to
present fairly the financial position, results of operations and cash flows for the interim periods
reported. This Report on Form 10-Q should be read in conjunction with Monsantos Report on Form
10-K for the fiscal year ended Aug. 31, 2009. Financial information for the first six months of
fiscal year 2010 should not be annualized because of the seasonality of the companys business.
NOTE 2. NEW ACCOUNTING STANDARDS
In January 2010, the FASB issued an amendment to the Fair Value Measurements and Disclosures topic
of the ASC. This amendment requires disclosures about transfers into and out of Levels 1 and 2 and
separate disclosures about purchases, sales, issuances, and settlements relating to Level 3
measurements. It also clarifies existing fair value disclosures about the level of disaggregation
and about inputs and valuation techniques used to measure fair value. This amendment is effective
for periods beginning after Dec. 15, 2009, except for the requirement to provide the Level 3
activity of purchases, sales, issuances, and settlements, which will be effective for fiscal years
beginning after Dec. 15, 2010. Accordingly, Monsanto will adopt this amendment in third quarter
2010, except for the additional Level 3 requirements which will be adopted in fiscal year 2011. The
company is currently evaluating the disclosure impact of adopting this standard on the consolidated
financial statements.
In June 2009, the FASB issued its ASC Topic 105, Generally Accepted Accounting Principles, which
became the single source of authoritative U.S. generally accepted accounting principles (GAAP)
(other than rules and interpretive releases of the U.S. Securities and Exchange Commission). The
ASC is topically based with topics organized by ASC number and updated with Accounting Standards
Updates (ASUs). ASUs will replace accounting guidance that historically was issued as FASB
Statements of Financial Accounting Standards (SFAS), FASB Interpretations (FIN), FASB Staff
Positions (FSP), Emerging Issues Task Force (EITF) Issues or other types of accounting standards.
The ASC became effective Nov. 30, 2009, for Monsanto and disclosures within this Quarterly Report
on Form 10-Q have been updated to reflect the change. The ASC does not change GAAP and did not
impact the companys consolidated financial statements.
8
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
In June 2009, the FASB issued a standard that requires an analysis to determine whether a variable
interest gives the entity a controlling financial interest in a variable interest entity. This
statement requires an ongoing reassessment and eliminates the quantitative approach previously
required for determining whether an entity is the primary beneficiary. This standard is effective
for fiscal years beginning after Nov. 15, 2009. Accordingly, Monsanto will adopt this standard in
fiscal year 2011. The company is currently evaluating the impact of adoption on the consolidated
financial statements.
In June 2009, the FASB issued a standard that removes the concept of a qualifying special-purpose
entity (QSPE) from GAAP and removes the exception from applying consolidation principles to a QSPE.
This standard also clarifies the requirements for isolation and limitations on portions of
financial assets that are eligible for sale accounting. This standard is effective for fiscal years
beginning after Nov. 15, 2009. Accordingly, Monsanto will adopt this standard in fiscal year 2011.
The company is currently evaluating the impact of adoption on its QSPE, other financing programs
and on the consolidated financial statements.
In April 2009, the FASB issued a standard that extends the previous disclosure requirements about
fair value of financial instruments to interim financial statements of publicly traded companies.
This standard requires that disclosures provide quantitative and qualitative information on fair
value estimates for all financial instruments not measured on the balance sheet at fair value, when
practicable, with the exception of certain financial instruments. This standard is effective
prospectively for interim reporting periods ending after June 15, 2009. Accordingly, Monsanto
adopted this standard in first quarter fiscal year 2010. See Note 12 Debt and Other Credit
Arrangements, Note 13 Fair Value Measurements and Note 14 Financial Instruments for the
disclosures required by this standard.
In December 2008, the FASB issued a standard that provides additional guidance regarding
disclosures about plan assets of defined benefit pension or other postretirement plans. This
standard is effective for financial statements issued for fiscal years ending after Dec. 15, 2009.
Accordingly, Monsanto will include the disclosure requirements of this standard in the Report on
Form 10-K for the fiscal year ended Aug. 31, 2010. The company is currently evaluating the
disclosure impact of adopting this standard on the consolidated financial statements.
In February 2008, the FASB issued a standard that delayed the effective date of the new guidance
regarding fair value measurement and disclosure for nonfinancial assets and liabilities to fiscal
years beginning after Nov. 15, 2008. Accordingly, Monsanto adopted the additional requirements of
the Fair Value Measurements and Disclosures topic of the ASC that were deferred by this standard in
first quarter fiscal year 2010. The adoption of this standard did not have an impact on the
companys consolidated financial statements. See Note 13 Fair Value Measurements for additional
discussion regarding fair value measurements.
In December 2007, the FASB issued a standard that requires an entity to clearly identify and
present its ownership interests in subsidiaries held by parties other than the entity in the
consolidated financial statements within the equity section but separate from the entitys equity.
It also requires the amount of consolidated net income attributable to the parent and to the
noncontrolling interest be clearly identified and presented on the face of the Statements of
Consolidated Operations; changes in ownership interest be accounted for similarly, as equity
transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity
investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary
be measured at fair value. This statement is effective for financial statements issued for fiscal
years beginning after Dec. 15, 2008. The provisions of the standard related to accounting for
changes in ownership are to be applied prospectively, except for the presentation and disclosure
requirements, which are to be applied retrospectively. Monsanto adopted this standard on Sept. 1,
2009, and the presentation and disclosure requirements of this standard were applied
retrospectively to all periods presented. The adoption of this standard did not have a material
impact on the consolidated financial statements, other than the following changes in presentation
of noncontrolling interests:
|
|
|
Consolidated net income was recast to include net income attributable to both the
company and noncontrolling interests in the Statements of Consolidated Operations. |
|
|
|
Noncontrolling interests were reclassified from other liabilities to equity, separate
from the parents shareowners equity, in the Condensed Statements of Consolidated
Financial Position. |
|
|
|
The Statements of Consolidated Cash Flows now begin with net income (including
noncontrolling interests) instead of net income attributable to Monsanto Company, with net
income from noncontrolling interests (previously,
|
9
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
|
|
|
minority interests) no longer a reconciling item in arriving at net cash provided by
operating activities, and the Statements of Consolidated Cash Flows were recast to include
dividend payments to noncontrolling interests. |
|
|
|
|
Interim Condensed Statements of Consolidated Shareowners Equity and Comprehensive
Income have been added to fulfill the disclosure requirements. |
NOTE 3. BUSINESS COMBINATIONS
Effective Sept. 1, 2009, Monsanto adopted the new guidance in the Business Combinations topic of
the ASC for acquisitions subsequent to that date.
2010 Acquisition: In October 2009, Monsanto acquired the remaining 51 percent equity interest in
Seminium, S.A. (Seminium), a leading Argentinean corn seed company. Acquisition costs were less
than $1 million for the six months ended Feb. 28, 2010, and classified as selling, general and
administrative expenses. The total fair value of Seminium was $36 million, and it was primarily
allocated to inventory, fixed assets, intangibles, and goodwill. This fair value includes
$20 million of cash paid (net of cash acquired) and $16 million for the fair value of Monsantos 49
percent equity interest in Seminium held prior to the acquisition. The primary items that generated
goodwill were the premiums paid by the company for the right to control the business acquired and
the value of the acquired assembled workforce. The goodwill is not deductible for tax purposes.
Income of approximately $12 million was recognized from the re-measurement to fair value of
Monsantos previous equity interest in Seminium and is included in other expense (income), net in
the Statements of Consolidated Operations for the six months ended Feb. 28, 2010. The measurement
period for purchase price allocations ends as soon as information on the facts and circumstances
becomes available, but does not exceed twelve months. If new information is obtained about facts
and circumstances that existed as of the acquisition date that, if known, would have affected the
measurement of the amounts recognized for assets acquired and liabilities assumed, Monsanto will
retrospectively adjust the amounts recognized as of the acquisition date.
2009 Acquisitions: In July 2009, Monsanto acquired the assets of WestBred, LLC, a Montana-based
company that specializes in wheat germplasm, for $49 million (net of cash acquired), inclusive of
transaction costs of $4 million. The acquisition will bolster the future growth of Monsantos seeds
and traits platform.
In December 2008, Monsanto acquired 100 percent of the outstanding stock of Aly Participacoes Ltda.
(Aly), which operates the sugarcane breeding and technology companies, CanaVialis S.A. and Alellyx
S.A., both of which are based in Brazil, for $264 million (net of cash acquired), inclusive of
transaction costs of less than $1 million.
In 2009, Monsanto paid approximately $5 million of contingent consideration related to fiscal year
2007 regional U.S. seed company acquisitions.
For all fiscal year 2010 and 2009 acquisitions described above, the business operations and
employees of the acquired entities were included within the Seeds and Genomics segment from their
respective dates of acquisition. These acquisitions were accounted for as purchase transactions.
Accordingly, the assets and liabilities of the acquired entities were recorded at their estimated
fair values at the dates of the acquisitions. The purchase price allocations for the first and
second quarter 2010 and the third and fourth quarter 2009 acquisitions are preliminary and are
subject to adjustment pending further assessments, including the valuation of certain assets.
Proforma information related to acquisitions is not presented because the impact of the
acquisitions on the companys consolidated results of operations is not considered to be
significant.
For acquisitions prior to fiscal year 2010, as of the acquisition dates, management began to assess
and formulate plans to restructure the acquired entities in accordance with business combination
accounting guidance. These activities primarily include the potential closure of certain acquired
subsidiaries. Through Feb. 28, 2010, estimated costs of $23 million have been recognized as
short-term liabilities in the purchase price allocations above, and $10 million has been charged
against those liabilities, primarily related to payments for employee terminations and entity
consolidation. As management finalizes
10
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
plans to integrate or restructure certain activities of the acquired entities, further liabilities
may be recorded as part of the purchase price allocation.
NOTE 4. CUSTOMER FINANCING PROGRAMS
Monsanto previously established a revolving financing program to provide financing of up to $250
million for selected customers in the United States through a third-party specialty lender. The
program was terminated in the third quarter of fiscal year 2009. Under the financing program,
Monsanto originated customer loans on behalf of the lender, which was a special purpose entity
(SPE) that Monsanto consolidated, pursuant to Monsantos credit and other underwriting guidelines
approved by the lender. Under the program, Monsanto serviced the loans and provided a first-loss
guarantee of up to $130 million. Following origination, the lender transferred the loans to
multi-seller commercial paper conduits through a nonconsolidated QSPE. Monsanto accounted for this
transaction as a sale, in accordance with the Transfers and Servicing topic of the ASC.
Monsanto had no ownership interest in the lender, the QSPE, or the loans. However, because Monsanto
substantively originated the loans through the SPE (which it consolidated) and partially guaranteed
and serviced the loans, Monsanto accounted for the program as if it were the originator of the
loans and the transferor selling the loans to the QSPE. Because QSPEs are excluded from the current
guidance within the Consolidation topic of the ASC, and Monsanto did not have the unilateral right
to liquidate the QSPE, the consolidation guidance did not have an effect on Monsantos accounting
for the U.S. customer financing program.
Monsanto accounted for the guarantee in accordance with the Guarantees topic of the ASC, which
requires that a guarantor recognize, at the inception of the guarantee, a liability for the fair
value of the guarantee obligation undertaken. Monsanto recorded its guarantee liability at a value
that approximated fair value (except that it did not discount credit losses because of the
short-term nature of the loans), primarily driven by expected future credit losses. Monsanto did
not recognize any servicing asset or liability because the servicing fee was considered adequate
compensation for the servicing activities. Servicing activities including discounts on the sale of
customer receivables resulted in income of $1 million for the six months ended Feb. 28, 2009.
Proceeds from customer loans sold through the financing program totaled $130 million for the first
six months of fiscal year 2009. These proceeds are included in net cash provided by operating
activities in the Statement of Consolidated Cash Flows. There were no loan balances outstanding as
of Feb. 28, 2010, or Aug. 31, 2009.
During the second quarter 2010, Monsanto began participating in a revolving financing program in
Brazil that allows Monsanto to transfer up to 1 billion Brazilian reais (approximately $550
million) in customer receivables to a QSPE. Third parties, primarily investment funds, hold an 88
percent senior interest in the QSPE, and Monsanto holds the remaining 12 percent subordinate
interest. Because QSPEs are excluded from the scope of the current guidance within the
Consolidation topic of the ASC, and Monsanto does not have the unilateral right to liquidate the
QSPE, the consolidation guidance does not have an effect on Monsantos accounting for this customer
financing program.
Monsantos investment in the QSPE was $4 million as of Feb. 28, 2010, and is included in other
assets in the Condensed Statements of Consolidated Financial Position and is classified as a debt
security. Interest earned on Monsantos investment in the QSPE was less than $1 million for the
three months ended Feb. 28, 2010, and is included in interest income on the Statements of
Consolidated Operations.
Under the financing program, Monsantos transfer of select customer receivables to the QSPE is
accounted for as a sale, in accordance with the Transfers and Servicing topic of the ASC. Monsanto
does not service the receivables; however, under the QSPE a recourse provision requires Monsanto to
cover the first 12 percent of credit losses within the program.
11
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
Proceeds from customer receivables sold through the financing program and derecognized from the
Condensed Statements of Consolidated Financial Position totaled $47 million in fiscal year 2010.
These proceeds are included in net cash provided by operating activities in the Statements of
Consolidated Cash Flows and are net of a loss on sale of receivables of $3 million for the six
months ended Feb. 28, 2010. The remaining receivable balance in the QSPE outstanding as of Feb. 28,
2010, was $43 million. Receivables are considered delinquent when payments are one day past due,
but the provisions on the financing program for non-performance start on the 15th day past due. If
a customer fails to pay an obligation when due, the provisions for bad debt on the program will be
accounted for as an expense by the QSPE and the investment on Monsantos Condensed Statements of
Consolidated Financial Position will be decreased. As of Feb. 28, 2010, there were no receivables
sold through this financing program that were delinquent. However, based on the companys
historical collection experience with these customers and a current assessment of credit exposure,
Monsanto recorded its recourse provision at $2 million as of Feb. 28, 2010. Adverse changes in the
actual loss rate would decrease Monsantos investment asset. The maximum potential amount of future
payments under the recourse provision was $6 million as of Feb. 28, 2010. If Monsanto is called
upon to make payments under the recourse provision, it would have the benefit under the financing
program of any amounts subsequently collected from the customer.
Monsanto has additional agreements with lenders to establish programs that provide financing of up
to 550 million Brazilian reais (approximately $300 million) for selected customers in Brazil. These
agreements qualify for sales treatment under the Transfers and Servicing topic of the ASC. Proceeds
from the transfer of receivables are included in net cash provided by operating activities in the
Statements of Consolidated Cash Flows. Proceeds from the transfer of receivables through the
program totaled $114 million and $91 million for the first six months of fiscal years 2010 and
2009, respectively. Monsanto provides a guarantee of the loans in the event of customer default.
The term of the guarantee is equivalent to the term of the bank loans. The liability for the
guarantees is recorded at an amount that approximates fair value and is based on the companys
historical collection experience with customers that participate in the program and a current
assessment of credit exposure. The guarantee liability recorded by Monsanto was $8 million and $6
million as of Feb. 28, 2010, and Aug. 31, 2009, respectively. If performance is required under the
guarantee, Monsanto may retain amounts that are subsequently collected from customers. The maximum
potential amount of future payments under the guarantee was $177 million as of Feb. 28, 2010. The
loan balance outstanding for these programs was $177 million and $160 million as of Feb. 28, 2010,
and Aug. 31, 2009, respectively. There were no delinquent loans as of Feb. 28, 2010, and there were
delinquent loans of $2 million as of Aug. 31, 2009.
Monsanto also has similar agreements with banks that provide financing to its customers in Brazil
through credit programs that are subsidized by the Brazilian government. In addition, there are
similar financing programs with financial institutions in the United States, Europe and Argentina.
Proceeds from the payment of receivables are included in net cash provided by operating activities
in the Statements of Consolidated Cash Flows and totaled $103 million and $51 million for the first
six months of fiscal years 2010 and 2009, respectively. Under most of these programs, Monsanto
provides a guarantee of the loans in the event of customer default. The terms of the guarantees are
equivalent to the terms of the bank loans. The liability for the guarantees is recorded at an
amount that approximates fair value and is based on the companys historical collection experience
with customers that participate in the program and a current assessment of credit exposure. The
guarantee liability recorded by Monsanto was $4 million and $5 million as of Feb. 28, 2010, and
Aug. 31, 2009, respectively. If performance is required under the guarantee, Monsanto may retain
amounts that are subsequently collected from customers. The maximum potential amount of future
payments under the guarantees was $52 million as of Feb. 28, 2010. The loan balance outstanding for
these programs was $52 million and $48 million as of Feb. 28, 2010, and Aug. 31, 2009,
respectively.
In August 2009, Monsanto entered into an agreement in the United States to sell customer
receivables up to a maximum of $500 million and to service such accounts. The program will
terminate in August 2012. These receivables qualify for sales treatment under the Transfers and
Servicing topic of the ASC and accordingly, the proceeds are included in net cash provided by
operating activities in the Statements of Consolidated Cash Flows. The gross amount of receivables
sold totaled $2 million for the first six months of fiscal year 2010. The agreement includes
recourse provisions and thus a liability was established at the time of sale which approximates
fair value based upon the companys historical collection experience with such receivables and a
current assessment of credit exposure. The recourse liability recorded by Monsanto was $2 million
as of Feb. 28, 2010, and Aug. 31, 2009. The maximum potential amount of future payments under the
recourse provisions of the agreement was $4 million as of Feb. 28, 2010. The outstanding balance of
the receivables sold was $14 million and $319
12
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
million as of Feb. 28, 2010, and Aug. 31, 2009, respectively. There were delinquent accounts of $14
million as of Feb. 28, 2010, and there were no delinquent accounts as of Aug. 31, 2009.
Monsanto also sells accounts receivable in European regions, both with and without recourse. These
sales qualify for sales treatment under the Transfers and Servicing topic of the ASC and
accordingly, the proceeds are included in net cash provided by operating activities in the
Statements of Consolidated Cash Flows. The gross amounts of receivables sold totaled $15 million
and $1 million for the first six months of fiscal years 2010 and 2009, respectively. The liability
for the guarantees for sales with recourse is recorded at an amount that approximates fair value
and is based on the companys historical collection experience for the customers associated with
the sale of the receivables and a current assessment of credit exposure. The liability recorded by
Monsanto was less than $1 million as of Feb. 28, 2010, and Aug. 31, 2009. The maximum potential
amount of future payments under the recourse provisions of the agreements was $5 million as of Feb.
28, 2010. The outstanding balance of the receivables sold was $5 million and $57 million as of Feb.
28, 2010, and Aug. 31, 2009, respectively. There were no delinquent loans as of Feb. 28, 2010, or
Aug. 31, 2009.
Restructuring charges were recorded in the Statements of Consolidated Operations as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
(Dollars in millions) |
|
Feb. 28, 2010 |
|
|
Feb. 28, 2010 |
|
|
|
|
|
Costs of
Goods Sold(1) |
|
$ |
(54 |
) |
|
$ |
(54 |
) |
Restructuring
Charges, Net(1)(2) |
|
|
(30 |
) |
|
|
(44 |
) |
|
|
|
|
Loss from Continuing Operations Before Income Taxes |
|
|
(84 |
) |
|
|
(98 |
) |
Income Tax Benefit |
|
|
30 |
|
|
|
31 |
|
|
|
|
|
Net Loss |
|
$ |
(54 |
) |
|
$ |
(67 |
) |
|
|
|
|
|
|
|
(1) |
|
For the three months and six months ended Feb. 28, 2010, the $54 million of
restructuring charges recorded in cost of goods sold related to the Seeds and Genomics
segment. For the three months ended Feb. 28, 2010, the $30 million of restructuring charges
recorded in restructuring charges, net were split by segment as follows: $25 million in
Agricultural Productivity and $5 million in Seeds and Genomics. For the six months ended Feb.
28, 2010, the $44 million of restructuring charges were split by segment as follows: $36
million in Agricultural Productivity and $8 million in Seeds and Genomics. |
|
(2) |
|
The restructuring charges for the three and six months ended Feb. 28, 2010, include
reversals of $9 million and $11 million, respectively, related to the 2009 Restructuring Plan. |
On June 23, 2009, the companys Board of Directors approved a restructuring plan (2009
Restructuring Plan) to take future actions to reduce costs in light of the changing market supply
environment for glyphosate. The company created a separate division for its ROUNDUP and other
herbicides business, which is expected to better align spending and working capital needs. This
action is designed to enable Monsanto to stabilize the ROUNDUP business and allow it to deliver
optimal gross profit and a sustainable level of operating cash in the coming years. The company
also announced that it will take steps to better align the resources of its global seeds and traits
business. These actions include certain product and brand rationalization within the vegetables and
U.S. corn businesses. On Sept. 9, 2009, the company committed to take additional actions related to
the previously announced restructuring plan. The plan is expected to be completed by the end of
fiscal year 2010.
13
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
The following table displays the pretax charges of $84 million and $98 million incurred by
segment under the 2009 Restructuring Plan for the three and six months ended Feb. 28, 2010,
respectively, as well as the cumulative pretax charges of $504 million under the 2009 Restructuring
Plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, 2010 |
|
|
Six Months Ended Feb. 28, 2010 |
|
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
(Dollars in millions) |
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
|
|
|
|
|
|
|
|
Work Force Reductions |
|
$ |
3 |
|
|
$ |
1 |
|
|
$ |
4 |
|
|
$ |
4 |
|
|
$ |
11 |
|
|
$ |
15 |
|
Facility Closures / Exit Costs |
|
|
2 |
|
|
|
24 |
|
|
|
26 |
|
|
|
3 |
|
|
|
25 |
|
|
|
28 |
|
Asset
Impairments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
1 |
|
Inventory |
|
|
54 |
|
|
|
|
|
|
|
54 |
|
|
|
54 |
|
|
|
|
|
|
|
54 |
|
|
|
|
Total
Restructuring Charges, Net |
|
$ |
59 |
|
|
$ |
25 |
|
|
$ |
84 |
|
|
$ |
62 |
|
|
$ |
36 |
|
|
$ |
98 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative Amount through Feb. 28, 2010 |
|
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
(Dollars in millions) |
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
Work Force Reductions |
|
$ |
179 |
|
|
$ |
74 |
|
|
$ |
253 |
|
Facility Closures / Exit Costs |
|
|
6 |
|
|
|
72 |
|
|
|
78 |
|
Asset Impairments |
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment |
|
|
32 |
|
|
|
4 |
|
|
|
36 |
|
Inventory |
|
|
78 |
|
|
|
|
|
|
|
78 |
|
Other intangible assets |
|
|
59 |
|
|
|
|
|
|
|
59 |
|
|
Total Restructuring Charges, Net |
|
$ |
354 |
|
|
$ |
150 |
|
|
$ |
504 |
|
|
The companys written human resource policies are indicative of an ongoing benefit arrangement
with respect to severance packages. Benefits paid pursuant to an ongoing benefit arrangement are
specifically excluded from the Exit or Disposal Cost Obligations topic of the ASC, therefore
severance charges incurred in connection with the 2009 Restructuring Plan are accounted for when
probable and estimable as required under the Compensation Nonretirement Postemployment Benefits
topic of the ASC.
In the six months ended Feb. 28, 2010, pretax restructuring charges of $98 million were recorded.
The $15 million in work force reductions relate primarily to Europe. The facility closures/exit
costs of $28 million relate primarily to the finalization of the termination of a chemical supply
contract in the United States. In asset impairments, inventory impairments of $54 million recorded
in cost of goods sold related to discontinued corn seed products in the United States.
The following table summarizes the activities related to the companys 2009 Restructuring Plan. See
Note 3 Business Combinations for restructuring reserves related to acquisitions.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Work Force |
|
|
Facility Closures / |
|
|
Asset |
|
|
|
|
(Dollars in millions) |
|
Reductions |
|
|
Exit Costs |
|
|
Impairments |
|
|
Total |
|
|
Beginning Liability as of Aug. 31, 2009 |
|
$ |
216 |
|
|
$ |
50 |
|
|
$ |
|
|
|
$ |
266 |
|
Restructuring charges recognized in first six
months of fiscal year 2010 |
|
|
15 |
|
|
|
28 |
|
|
|
55 |
|
|
|
98 |
|
Cash payments |
|
|
(101 |
) |
|
|
(23 |
) |
|
|
|
|
|
|
(124 |
) |
Asset impairments and write-offs |
|
|
|
|
|
|
|
|
|
|
(55 |
) |
|
|
(55 |
) |
Foreign currency impact |
|
|
(1 |
) |
|
|
|
|
|
|
|
|
|
|
(1 |
) |
|
Ending Liability as of Feb. 28, 2010 |
|
$ |
129 |
|
|
$ |
55 |
|
|
$ |
|
|
|
$ |
184 |
|
|
14
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
NOTE 6. RECEIVABLES
Trade receivables on the Condensed Statements of Consolidated Financial Position are net of
allowances of $180 million and $162 million as of Feb. 28, 2010, and Aug. 31, 2009, respectively.
Long-term receivables on the Condensed Statements of Consolidated Financial Position are net of
allowances of $179 million and $172 million as of Feb. 28, 2010, and Aug. 31, 2009, respectively.
NOTE 7. INVENTORY
Components of inventory are:
|
|
|
|
|
|
|
|
|
|
|
|
As of Feb. 28, |
|
|
As of Aug. 31, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
Finished Goods |
|
$ |
1,429 |
|
|
$ |
1,362 |
|
Goods In Process |
|
|
1,433 |
|
|
|
1,340 |
|
Raw Materials and Supplies |
|
|
490 |
|
|
|
417 |
|
|
|
|
|
|
|
|
|
Inventory at FIFO Cost |
|
|
3,352 |
|
|
|
3,119 |
|
Excess of FIFO over LIFO Cost |
|
|
(153 |
) |
|
|
(185 |
) |
|
|
|
|
|
|
|
|
Total |
|
$ |
3,199 |
|
|
$ |
2,934 |
|
|
|
|
|
|
|
|
|
NOTE 8. GOODWILL AND OTHER INTANGIBLE ASSETS
Changes in the net carrying amount of goodwill for the first six months of fiscal year 2010, by
segment, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
(Dollars in millions) |
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
Balance as of Aug. 31, 2009 |
|
$ |
3,156 |
|
|
$ |
62 |
|
|
$ |
3,218 |
|
Acquisition activity (see Note 3) |
|
|
13 |
|
|
|
|
|
|
|
13 |
|
Effect of foreign currency translation adjustments and other |
|
|
(5 |
) |
|
|
|
|
|
|
(5 |
) |
|
Balance as of Feb. 28, 2010 |
|
$ |
3,164 |
|
|
$ |
62 |
|
|
$ |
3,226 |
|
|
In the six months ended Feb. 28, 2010, goodwill increased due to the 2010 acquisition of
Seminium and the updating of the preliminary purchase price allocations for some of the 2009
acquisitions. See Note 3 Business Combinations for further information.
15
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
Information regarding the companys other intangible assets is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of Feb. 28, 2010 |
|
As of Aug. 31, 2009 |
|
|
|
Carrying |
|
|
Accumulated |
|
|
|
|
|
|
Carrying |
|
|
Accumulated |
|
|
|
|
(Dollars in millions) |
|
Amount |
|
|
Amortization |
|
|
Net |
|
|
Amount |
|
|
Amortization |
|
|
Net |
|
|
|
|
Acquired Germplasm |
|
$ |
1,168 |
|
|
$ |
(622 |
) |
|
$ |
546 |
|
|
$ |
1,172 |
|
|
$ |
(604 |
) |
|
$ |
568 |
|
Acquired
Biotechnology Intellectual Property |
|
|
835 |
|
|
|
(625 |
) |
|
|
210 |
|
|
|
829 |
|
|
|
(589 |
) |
|
|
240 |
|
Trademarks |
|
|
347 |
|
|
|
(87 |
) |
|
|
260 |
|
|
|
345 |
|
|
|
(81 |
) |
|
|
264 |
|
Customer Relationships |
|
|
321 |
|
|
|
(100 |
) |
|
|
221 |
|
|
|
317 |
|
|
|
(88 |
) |
|
|
229 |
|
Other |
|
|
123 |
|
|
|
(47 |
) |
|
|
76 |
|
|
|
110 |
|
|
|
(40 |
) |
|
|
70 |
|
|
|
|
Total |
|
$ |
2,794 |
|
|
$ |
(1,481 |
) |
|
$ |
1,313 |
|
|
$ |
2,773 |
|
|
$ |
(1,402 |
) |
|
$ |
1,371 |
|
|
|
|
The increases in other intangible assets during the six months ended Feb. 28, 2010, primarily
resulted from the acquisition of Seminium described in Note 3 Business Combinations.
Total amortization expense of other intangible assets was $39 million in second quarter of fiscal
year 2010 and $39 million in second quarter of fiscal year 2009. Total amortization expense of
other intangible assets was $79 million for the six months ended Feb. 28, 2010, and $72 million for
the six months ended Feb. 28, 2009. Estimated intangible asset amortization expense for each of the
five succeeding fiscal years for owned assets as of Feb. 28, 2010, has not changed significantly
from the amounts disclosed in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31,
2009.
NOTE 9. INVESTMENTS AND EQUITY AFFILIATES
Investments
Monsanto has investments in long-term equity securities, which are considered available-for-sale.
As of Feb. 28, 2010, and Aug. 31, 2009, these long-term debt and equity securities are recorded in
other assets in the Condensed Statements of Consolidated Financial Position at a fair value of $36
million and $25 million, respectively. Net unrealized losses (net of deferred taxes) of $4 million
and $6 million are included in accumulated other comprehensive loss in shareowners equity related
to these investments as of Feb. 28, 2010, and Aug. 31, 2009, respectively.
Equity Affiliates
Monsanto owns a 19 percent interest in a seed supplier that produces, conditions, and distributes
corn and soybean seeds. Monsanto is accounting for this investment as an equity method investment
as Monsanto has the ability to exercise significant influence over the seed supplier. As of Feb.
28, 2010, and Aug. 31, 2009, this investment is recorded in other assets in the Condensed
Statements of Consolidated Financial Position at $62 million and $60 million, respectively.
Monsanto purchased $101 million and $109 million of inventory from the seed supplier for the three
and six months ended Feb. 28, 2010, respectively, and $41 million and $140 million for the three
and six months ended Feb. 28, 2009. There were no sales of inventory to the seed supplier in either
2010 or 2009. As of Feb. 28, 2010, and Aug. 31, 2009, the amount payable to the seed supplier was
$18 million and $84 million, respectively, and recorded in accounts payable in the Condensed
Statements of Consolidated Financial Position. As of Feb. 28, 2010, there were no prepayments,
while the prepayment as of Aug. 31, 2009, was $5 million, included in other current assets in the
Condensed Statements of Consolidated Financial Position related to inventory delivered in fiscal
year 2010.
16
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
NOTE 10. DEFERRED REVENUE
In first quarter 2008, Monsanto entered into a corn herbicide tolerance and insect control trait
technologies agreement with Pioneer Hi-Bred International, Inc., a wholly-owned subsidiary of E. I.
du Pont de Nemours and Company. Among its provisions, the agreement modified certain existing corn
license agreements between the parties, included provisions under which the parties agreed not to
assert certain intellectual property rights against each other, and granted each party the right to
use certain regulatory data of the other in order to develop additional products. As a result of
the new agreement which requires fixed annual payments, the company recorded a receivable and
deferred revenue of $635 million in first quarter 2008. Cumulative cash receipts will be $725
million over an eight-year period. Revenue of $20 million related to this agreement was recorded
for the three months ended Feb. 28, 2010, and Feb. 28, 2009, and revenue of $40 million was
recorded for the six months ended Feb. 28, 2010, and Feb. 28, 2009. As of Feb. 28, 2010, and Aug.
31, 2009, the remaining receivable balance is $462 million and $543 million, respectively. The
majority of this balance is included in long-term receivables, and the current portion is included
in trade receivables. As of Feb. 28, 2010, and Aug. 31, 2009, the remaining deferred revenue
balance is $436 million and $476 million, respectively. The majority of this balance is included in
long-term deferred revenue, and the current portion is included in deferred revenue in the
Condensed Statements of Consolidated Financial Position. The interest portion of this receivable is
reported in interest income and totaled $4 million and $8 million for the three and six months
ended Feb. 28, 2010, respectively. Interest income for the three and six months ended Feb. 28,
2009, was $5 million and $10 million, respectively.
In third quarter 2008, Monsanto and Syngenta entered into a GENUITY ROUNDUP READY 2 YIELD Soybean
License Agreement. The agreement grants Syngenta access to Monsantos GENUITY ROUNDUP READY 2 YIELD
Soybean technology in consideration of royalty payments from Syngenta, based on sales. Under this
agreement Syngenta will fulfill the contractual sales volumes over a nine-year period. The minimum
obligation from Syngenta over this period is $81 million. As of Feb. 28, 2010, and Aug. 31, 2009,
the remaining receivable balance is $71 million and $70 million, respectively, related to the net
present value of expected payments under this agreement. The majority of this balance is included
in long-term receivables on the Condensed Statements of Consolidated Financial Position and the
current portion is included in trade receivables. The interest portion of this receivable is
reported in interest income in the Statements of Consolidated Operations and was less than $1
million and $1 million for both the three and six months ended Feb. 28, 2010, and Feb. 28, 2009. As
of Feb. 28, 2010, and Aug. 31, 2009, the remaining deferred revenue balance of $66 million and $70
million, respectively, is included in long-term deferred revenue in the Condensed Statements of
Consolidated Financial Position and the current portion is included in deferred revenue.
NOTE 11. INCOME TAXES
Management regularly assesses the tax risk of the companys tax return filing positions for all
open years and establishes reserves accordingly. In the first half of 2010, statutes expired in
several jurisdictions and several domestic and ex-US tax matters were resolved favorably. In
addition, favorable adjustments were recorded as a result of the preparation of tax returns in
several jurisdictions. Primarily as a result of these items, Monsanto recorded a tax benefit of $32
million in the first half of 2010.
During the first half of 2009 several domestic and ex-US tax matters were resolved favorably. On
Oct. 3, 2008, the retroactive extension of the research and development credit was enacted as part
of the Emergency Economic Stabilization Act of 2008. During the first half of 2009, Monsanto
recorded an income tax benefit of $95 million primarily as a result of these items.
17
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
NOTE 12. DEBT AND OTHER CREDIT ARRANGEMENTS
Monsanto plans to issue new fixed-rate debt on or before Aug. 15, 2012, to repay $486 million of
73/8% Senior Notes that are due on Aug. 15, 2012. In March 2009, the company entered into
forward-starting interest rate swaps with a total notional amount of $250 million. The purpose of
the swaps was to hedge the variability of the forecasted interest payments on this expected debt
issuance that may result from changes in the benchmark interest rate before the debt is issued.
Unrealized gains, net of tax, of $12 million and $9 million were recorded in accumulated other
comprehensive loss to reflect the after tax change in the fair value of the forward-starting
interest rate swaps as of Feb. 28, 2010, and Aug. 31, 2009, respectively. These swaps are accounted
for under the Derivatives and Hedging topic of the ASC.
As of Feb. 28, 2010, Monsanto did not have any commercial paper outstanding.
The fair value of the total short-term debt was $114 million and $79 million as of Feb. 28, 2010,
and Aug. 31, 2009, respectively. The fair value of the total long-term debt was $1,843 million and
$1,863 million as of Feb. 28, 2010, and Aug. 31, 2009, respectively.
NOTE 13. FAIR VALUE MEASUREMENTS
Effective Sept. 1, 2008, Monsanto adopted a standard which provides a framework for measuring fair
value. The standard also eliminates the deferral of gains and losses at inception associated with
certain derivative contracts whose fair value was not evidenced by observable market data. The
standard requires that the impact of this change in accounting for derivative contracts be recorded
as an adjustment to opening retained earnings in the period of adoption. Monsanto did not have any
deferred gains or losses at inception of derivative contracts and therefore no adjustment to
opening retained earnings was made upon adoption of the standard.
Monsanto determines the fair market value of its financial assets and liabilities based on quoted
market prices, estimates from brokers, and other appropriate valuation techniques. The company uses
the fair value hierarchy established in the Fair Value Measurements and Disclosures topic of the
ASC, which requires an entity to maximize the use of observable inputs and minimize the use of
unobservable inputs when measuring fair value. The hierarchy contains three levels as follows, with
Level 3 representing the lowest level of input:
Level 1 Values based on unadjusted quoted prices in active markets that are accessible at
the measurement date for identical assets or liabilities.
Level 2 Values based on quoted prices for similar instruments in active markets, quoted
prices for identical or similar instruments in markets that are not active, or model-based
valuation techniques for which all significant assumptions are observable in the market.
Level 3 Values generated from model-based techniques that use significant assumptions not
observable in the market. These unobservable assumptions would reflect our own estimates of
assumptions that market participants would use in pricing the asset or liability. Valuation
techniques could include use of option pricing models, discounted cash flow models and similar
techniques.
The following tables set forth by level Monsantos assets and liabilities that were accounted for
at fair value on a recurring basis as of Feb. 28, 2010, and Aug. 31, 2009. As required by the Fair
Value Measurements and Disclosures topic of the ASC, assets and liabilities are classified in their
entirety based on the lowest level of input that is a significant component of the fair value
measurement. Monsantos assessment of the significance of a particular input to the fair value
measurement requires
18
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
judgment and may affect the classification of fair value assets and liabilities within the fair
value hierarchy levels.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements at Feb. 28, 2010 Using |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collateral |
|
|
Net |
|
(Dollars in millions) |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Offset(1) |
|
|
Balance |
|
|
Assets at Fair Value: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
1,276 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
1,276 |
|
Debt and Equity securities |
|
|
32 |
|
|
|
|
|
|
|
4 |
|
|
|
|
|
|
|
36 |
|
Derivative assets related to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency |
|
|
|
|
|
|
32 |
|
|
|
|
|
|
|
|
|
|
|
32 |
|
Interest rates |
|
|
|
|
|
|
19 |
|
|
|
|
|
|
|
|
|
|
|
19 |
|
Commodities |
|
|
11 |
|
|
|
6 |
|
|
|
|
|
|
|
(11 |
) |
|
|
6 |
|
|
Total Assets at Fair Value |
|
$ |
1,319 |
|
|
$ |
57 |
|
|
$ |
4 |
|
|
$ |
(11 |
) |
|
$ |
1,369 |
|
|
Liabilities at Fair Value: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liabilities related to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency |
|
|
|
|
|
|
15 |
|
|
|
|
|
|
|
|
|
|
|
15 |
|
Commodities |
|
|
4 |
|
|
|
25 |
|
|
|
|
|
|
|
(4 |
) |
|
|
25 |
|
|
Total Liabilities at Fair Value |
|
$ |
4 |
|
|
$ |
40 |
|
|
$ |
|
|
|
$ |
(4 |
) |
|
$ |
40 |
|
|
|
|
|
|
Fair Value Measurements at Aug. 31, 2009 Using |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Collateral |
|
|
Net |
|
(Dollars in millions) |
|
Level 1 |
|
|
Level 2 |
|
|
Level 3 |
|
|
Offset(1) |
|
|
Balance |
|
|
Assets at Fair Value: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash equivalents |
|
$ |
1,548 |
|
|
$ |
|
|
|
$ |
|
|
|
$ |
|
|
|
$ |
1,548 |
|
Equity securities |
|
|
25 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
25 |
|
Derivative assets related to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency |
|
|
|
|
|
|
34 |
|
|
|
|
|
|
|
|
|
|
|
34 |
|
Interest rates |
|
|
|
|
|
|
14 |
|
|
|
|
|
|
|
|
|
|
|
14 |
|
Commodities |
|
|
2 |
|
|
|
|
|
|
|
|
|
|
|
(2 |
) |
|
|
|
|
|
Total Assets at Fair Value |
|
$ |
1,575 |
|
|
$ |
48 |
|
|
$ |
|
|
|
$ |
(2 |
) |
|
$ |
1,621 |
|
|
Liabilities at Fair Value: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Derivative liabilities related to: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign currency |
|
|
|
|
|
|
37 |
|
|
|
|
|
|
|
|
|
|
|
37 |
|
Commodities |
|
|
93 |
|
|
|
31 |
|
|
|
|
|
|
|
(93 |
) |
|
|
31 |
|
|
Total Liabilities at Fair Value |
|
$ |
93 |
|
|
$ |
68 |
|
|
$ |
|
|
|
$ |
(93 |
) |
|
$ |
68 |
|
|
(1) |
|
As allowed by the Derivatives and Hedging topic of the ASC, commodity derivative
assets and liabilities have been offset by cash collateral due and paid under a master netting
arrangement. |
As discussed in Note 4 Customer Financing Programs, Monsanto purchased available-for-sale
securities in second quarter of fiscal year 2010, which are recorded in other assets in the
Condensed Statements of Consolidated Financial Position. The initial investment is measured at fair value using
an independent pricing source and subsequently adjusted for expected future credit losses. Because
the credit losses are based on internal assumptions, these investments are considered to be Level
3.
19
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
The following table summarizes the changes in fair value of the Level 3 asset as of Feb. 28, 2010.
|
|
|
|
|
|
|
|
|
|
|
|
Three Months |
|
|
Six Months Ended |
|
|
|
Ended |
|
Ended |
(Dollars in millions) |
|
Feb. 28, 2010 |
|
|
Feb. 28, 2010 |
|
|
|
|
Beginning Balance |
|
$ |
|
|
|
$ |
|
|
Purchases,
sales, issuances, settlements and payments received |
|
|
6 |
|
|
|
6 |
|
Unrealized
loss in investments included in accumulated other comprehensive
loss |
|
|
(2 |
) |
|
|
(2 |
) |
|
|
|
Ending
Balance |
|
$ |
4 |
|
|
$ |
4 |
|
|
|
|
Disclosures for nonfinancial assets and liabilities that are measured at fair value, but are
recognized and disclosed as fair value on a nonrecurring basis, were required prospectively
beginning Sept. 1, 2009. During the three and six months ended Feb. 28, 2010, there were no
significant measurements of assets or liabilities at fair value on a nonrecurring basis subsequent
to their initial recognition.
The recorded amounts of cash, trade receivables, miscellaneous receivables, third-party guarantees,
accounts payable, grower accruals, accrued marketing programs, miscellaneous short-term accruals,
and short-term debt approximate their fair values as of Feb. 28, 2010, and Aug. 31, 2009.
NOTE 14. FINANCIAL INSTRUMENTS
Monsantos business and activities expose it to a variety of market risks, including risks related
to changes in commodity prices, foreign-currency exchange rates and interest rates. These financial
exposures are monitored and managed by the company as an integral part of its market risk
management program. This program recognizes the unpredictability of financial markets and seeks to
reduce the potentially adverse effects that market volatility could have on operating results. As
part of its market risk management strategy, Monsanto uses derivative instruments to protect fair
values and cash flows from fluctuations caused by volatility in currency exchange rates, commodity
prices and interest rates.
Cash Flow Hedges
The company uses foreign-currency options and foreign-currency forward contracts as hedges of
anticipated sales or purchases denominated in foreign currencies. The company enters into these
contracts to protect itself against the risk that the eventual net cash flows will be adversely
affected by changes in exchange rates.
Monsantos commodity price risk management strategy is to use derivative instruments to minimize
significant unanticipated earnings fluctuations that may arise from volatility in commodity prices.
Price fluctuations in commodities, mainly in corn and soybeans, can cause the actual prices paid to
production growers for corn and soybean seeds to differ from anticipated cash outlays. Monsanto
uses commodity futures and options contracts to manage these risks. Monsantos energy risk
management strategy is to use derivative instruments to minimize significant unanticipated
manufacturing cost fluctuations that may arise from volatility in natural gas prices and diesel
prices.
Monsantos interest rate risk management strategy is to use derivative instruments to minimize
significant unanticipated earnings fluctuations that may arise from volatility in interest rates of
the companys borrowings and to manage the interest rate sensitivity of its debt.
For derivative instruments that are designated and qualify as a cash flow hedge, the effective
portion of the gain or loss on the derivative is reported as a component of other comprehensive
income and reclassified into earnings in the same period or periods during which the hedged
transaction affects earnings. Gains and losses on the derivative representing either hedge
ineffectiveness or hedge components excluded from the assessment of effectiveness are recognized in
current earnings.
The maximum term over which the company is hedging exposures to the variability of cash flow (for
all forecasted transactions) is 18 months for foreign-currency hedges, 49 months for commodity
hedges and 30 months for interest rate
20
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
hedges. During the next 12 months, a pretax net loss of
approximately $40 million will be reclassified from other
comprehensive income into earnings. During the three and six months ended Feb. 28, 2010, a loss of
$25 million and $29 million, respectively, was reclassified into earnings as a result of the
discontinuance of cash flow hedges because it was probable that the original forecasted transaction
would not occur by the end of the originally specified time period. No cash flow hedges were
discontinued during the three and six months ended Feb. 28, 2009.
Fair-Value Hedges
The company uses commodity futures and options contracts as fair-value hedges to manage the value
of its soybean inventory. For derivative instruments that are designated and qualify as a
fair-value hedge, both the gain or loss on the derivative and the offsetting loss or gain on the
hedged item attributable to the hedged risk are recognized in current earnings.
The difference between the carrying value and the fair value of hedged items classified as
fair-value hedges was offset by the change in fair value of the related derivatives. Accordingly,
hedge ineffectiveness for fair-value hedges, determined in accordance with the Derivatives and
Hedging topic of the ASC, had an immaterial effect on earnings in the three and six months ended
Feb. 28, 2010, and Feb. 28, 2009. No fair-value hedges were discontinued during the three and six
months ended Feb. 28, 2010, or Feb. 28, 2009.
Net Investment Hedges
In order to protect the value of its investment from adverse changes in exchange rates, the company
may, from time to time, hedge a portion of its net investment in one or more of its foreign
subsidiaries. Gains or losses on derivative instruments that are designated as a net investment
hedge are included in accumulated foreign currency translation adjustment and reclassified into
earnings in the period during which the hedged net investment is sold or liquidated.
Derivatives Not Designated as Hedging Instruments
The company uses foreign-currency contracts to hedge the effects of fluctuations in exchange rates
on foreign-currency-denominated third-party and intercompany receivables and payables. Both the
gain or loss on the derivative and the offsetting loss or gain on the hedged item attributable to
the hedged risk are recognized in current earnings.
The company uses commodity option contracts to hedge anticipated cash payments to corn growers in
Mexico and Brazil, which can fluctuate based on changes in corn price. Because these option
contracts do not meet the provisions specified by the Derivatives and Hedging topic of the ASC,
they do not qualify for hedge accounting treatment. Accordingly, the gain or loss on these
derivatives is recognized in current earnings.
To reduce credit exposure in Latin America, Monsanto collects payments on certain customer accounts
in grain. Such payments in grain are negotiated at the time Monsantos products are sold to the
customers and are valued at the prevailing grain commodity prices. By entering into forward sales
contracts related to grain, Monsanto may choose to mitigate the commodity price exposure from the
time a contract is signed with a customer until the time the grain is collected from the customer
by a grain merchant on Monsantos behalf. The forward sales contracts are not designated as hedging
instruments under the Derivatives and Hedging topic of the ASC. Accordingly, the gain or loss on
these derivatives is recognized in current earnings.
Financial instruments are neither held nor issued by the company for trading purposes.
21
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
The notional amounts of the companys derivative instruments outstanding as of Feb. 28, 2010, and
Aug. 31, 2009, were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
As of Feb. 28, |
|
As of Aug. 31, |
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
|
|
Derivatives Designated as Hedges: |
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
$ |
524 |
|
|
$ |
718 |
|
Commodity contracts |
|
|
712 |
|
|
|
716 |
|
Interest rate contracts |
|
|
250 |
|
|
|
250 |
|
|
|
|
Total Derivatives Designated as Hedges |
|
$ |
1,486 |
|
|
$ |
1,684 |
|
|
|
|
Derivatives Not Designated as Hedges: |
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
$ |
998 |
|
|
$ |
1,391 |
|
Commodity contracts |
|
|
185 |
|
|
|
1 |
|
|
|
|
Total Derivatives Not Designated as Hedges |
|
$ |
1,183 |
|
|
$ |
1,392 |
|
|
|
|
The fair values of the companys derivative instruments outstanding as of Feb. 28, 2010, and
Aug. 31, 2009, were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Balance Sheet Location |
|
Fair Value(1) |
|
|
|
|
As of Feb. 28, |
|
As of Aug. 31, |
(Dollars in millions) |
|
|
|
2010 |
|
|
2009 |
|
|
|
|
Asset Derivatives: |
|
|
|
|
|
|
|
|
|
|
Derivatives designated as hedges: |
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Miscellaneous receivables |
|
$ |
19 |
|
|
$ |
14 |
|
Foreign exchange contracts |
|
Other assets |
|
|
9 |
|
|
|
13 |
|
Commodity contracts |
|
Other current assets(2) |
|
|
10 |
|
|
|
1 |
|
Commodity contracts |
|
Other assets(2) |
|
|
1 |
|
|
|
1 |
|
Interest rate contracts |
|
Other assets |
|
|
19 |
|
|
|
14 |
|
|
|
|
Total derivatives designated as hedges |
|
|
|
|
58 |
|
|
|
43 |
|
|
|
|
Derivatives not designated as hedges: |
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Miscellaneous receivables |
|
|
4 |
|
|
|
7 |
|
Commodity contracts |
|
Trade receivables, net |
|
|
2 |
|
|
|
|
|
Commodity contracts |
|
Miscellaneous receivables |
|
|
4 |
|
|
|
|
|
|
|
|
Total derivatives not designated as hedges |
|
|
|
|
10 |
|
|
|
7 |
|
|
|
|
Total Asset Derivatives |
|
|
|
$ |
68 |
|
|
$ |
50 |
|
|
|
|
Liability Derivatives: |
|
|
|
|
|
|
|
|
|
|
Derivatives designated as hedges: |
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Miscellaneous short-term accruals |
|
$ |
6 |
|
|
$ |
10 |
|
Commodity contracts |
|
Other current assets(2) |
|
|
3 |
|
|
|
85 |
|
Commodity contracts |
|
Other assets(2) |
|
|
|
|
|
|
7 |
|
Commodity contracts |
|
Miscellaneous short-term accruals |
|
|
10 |
|
|
|
19 |
|
Commodity contracts |
|
Other liabilities |
|
|
9 |
|
|
|
12 |
|
|
|
|
Total derivatives designated as hedges |
|
|
|
|
28 |
|
|
|
133 |
|
|
|
|
Derivatives not designated as hedges: |
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
Miscellaneous short-term accruals |
|
|
9 |
|
|
|
27 |
|
Commodity contracts |
|
Trade receivables, net |
|
|
5 |
|
|
|
|
|
Commodity contracts |
|
Other current assets(2) |
|
|
1 |
|
|
|
1 |
|
Commodity contracts |
|
Miscellaneous short-term accruals |
|
|
1 |
|
|
|
|
|
|
|
|
Total derivatives not designated as hedges |
|
|
|
|
16 |
|
|
|
28 |
|
|
|
|
Total Liability Derivatives |
|
|
|
$ |
44 |
|
|
$ |
161 |
|
|
|
|
|
|
|
(1) |
|
The carrying values of Monsantos derivative instruments approximate fair value. |
|
(2) |
|
As allowed by the Derivatives and Hedging topic of the ASC, corn and soybean
commodity derivative assets and liabilities have been offset by cash collateral due and paid
under a master netting arrangement. Therefore, all commodity contracts that are in an asset or
liability position are included in asset accounts within the Condensed Statements of
Consolidated Financial Position. See Note 13 Fair Value Measurements for a
reconciliation to amounts reported in the Condensed Statements of Consolidated Financial
Position as of Feb. 28, 2010, and Aug. 31, 2009. |
22
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
The gains and losses on the companys derivative instruments were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of Gain (Loss) |
|
|
|
|
|
|
|
|
Recognized in AOCI(1) |
|
|
Amount of Gain (Loss) |
|
|
|
|
|
(Effective Portion) |
|
|
Recognized in Income(2)(3) |
|
|
|
|
|
Three Months Ended Feb. 28, |
|
|
Three Months Ended Feb. 28, |
|
|
Income Statement |
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
Classification |
|
|
|
|
|
|
|
|
|
Derivatives Designated as Hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair-value hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commodity contracts(4) |
|
|
|
|
|
|
|
|
|
$ |
13 |
|
|
$ |
5 |
|
|
Cost of goods sold |
Cash flow hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
$ |
(1 |
) |
|
$ |
|
|
|
|
1 |
|
|
|
10 |
|
|
Net sales |
Foreign exchange contracts |
|
|
20 |
|
|
|
7 |
|
|
|
1 |
|
|
|
10 |
|
|
Cost of goods sold |
Commodity contracts |
|
|
(44 |
) |
|
|
(49 |
) |
|
|
(54 |
) |
|
|
20 |
|
|
Cost of goods sold |
Interest rate contracts |
|
|
8 |
|
|
|
|
|
|
|
(1 |
) |
|
|
(1 |
) |
|
Interest expense |
Net investment hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
|
|
|
|
|
(2 |
) |
|
|
|
|
|
|
|
|
|
N/A(5) |
|
|
|
|
|
|
|
|
|
Total Derivatives Designated as Hedges |
|
|
(17 |
) |
|
|
(44 |
) |
|
|
(40 |
) |
|
|
44 |
|
|
|
|
|
|
|
|
|
|
|
Income Statement |
Derivatives Not Designated as Hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts(6) |
|
|
|
|
|
|
|
|
|
|
(12 |
) |
|
|
3 |
|
|
Other expense, net |
|
|
|
|
|
|
|
|
|
Total
Derivatives Not Designated as Hedges |
|
|
|
|
|
|
|
|
|
|
(12 |
) |
|
|
3 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Derivatives |
|
$ |
(17 |
) |
|
$ |
(44 |
) |
|
$ |
(52 |
) |
|
$ |
47 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amount of Gain (Loss) |
|
|
|
|
|
|
|
|
Recognized in AOCI(1) |
|
|
Amount of Gain (Loss) |
|
|
|
|
|
(Effective Portion) |
|
|
Recognized in Income(2)(3) |
|
|
|
|
|
Six Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
|
Income Statement |
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
Classification |
|
|
|
Derivatives Designated as Hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair-value hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commodity contracts(4) |
|
|
|
|
|
|
|
|
|
$ |
8 |
|
|
$ |
22 |
|
|
Cost of goods sold |
Cash flow hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
$ |
(6 |
) |
|
$ |
84 |
|
|
|
2 |
|
|
|
11 |
|
|
Net sales |
Foreign exchange contracts |
|
|
11 |
|
|
|
65 |
|
|
|
8 |
|
|
|
12 |
|
|
Cost of goods sold |
Commodity contracts |
|
|
29 |
|
|
|
(244 |
) |
|
|
(68 |
) |
|
|
29 |
|
|
Cost of goods sold |
Interest rate contracts |
|
|
4 |
|
|
|
|
|
|
|
(3 |
) |
|
|
(3 |
) |
|
Interest expense |
Net investment hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts |
|
|
(3 |
) |
|
|
44 |
|
|
|
|
|
|
|
|
|
|
N/A(5) |
|
|
|
|
|
|
|
|
|
Total Derivatives Designated as Hedges |
|
|
35 |
|
|
|
(51 |
) |
|
|
(53 |
) |
|
|
71 |
|
|
|
|
|
|
|
|
|
|
|
|
Derivatives Not Designated as Hedges: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Foreign exchange contracts(6) |
|
|
|
|
|
|
|
|
|
|
(20 |
) |
|
|
7 |
|
|
Other expense, net |
Commodity contracts |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1 |
) |
|
Cost of goods sold |
|
|
|
|
|
|
|
|
|
Total
Derivatives Not Designated as Hedges |
|
|
|
|
|
|
|
|
|
|
(20 |
) |
|
|
6 |
|
|
|
|
|
|
|
|
|
|
|
|
Total Derivatives |
|
$ |
35 |
|
|
$ |
(51 |
) |
|
$ |
(73 |
) |
|
$ |
77 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Accumulated other comprehensive income (loss) (AOCI) |
|
(2) |
|
For derivatives designated as cash flow and net investment hedges under the
Derivatives and Hedging topic of the ASC, this represents the effective portion of the gain
(loss) reclassified from AOCI into income during the period. |
|
(3) |
|
Gain or loss on commodity cash flow hedges includes a loss of less than $1 million
and $4 million from ineffectiveness for the three months ended Feb. 28, 2010, and Feb. 28,
2009, respectively, and a gain of $1 million and a loss of $3 million from ineffectiveness for
the six months ended Feb. 28, 2010, and Feb. 28, 2009, respectively. Additionally, the gain or
loss on commodity cash flow hedges includes a loss from discontinued hedges of $25 million and
$29 million for the three and six months ended Feb. 28, 2010, respectively. No gains or losses
were excluded from the assessment of hedge effectiveness during the three or six months ended
Feb. 28, 2010, and Feb. 28, 2009. |
23
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED (continued)
|
|
|
|
(4) |
|
Gain on commodity fair value hedges is offset by a loss of $12 million and $5
million on the underlying hedged inventory for the three months ended Feb. 28, 2010, and Feb.
28, 2009, respectively, and a loss of $7 million and $17 million on the underlying hedged
inventory for the six months ended Feb. 28, 2010, and Feb. 28, 2009, respectively. A gain from
ineffectiveness of $1 million and less than $1 million during the three months ended Feb. 28,
2010, and Feb. 28, 2009, and a gain from ineffectiveness of $1 million and $5 million during
the six months ended Feb. 28, 2010, and Feb. 28, 2009, respectively, was included in cost of
goods sold. |
|
(5) |
|
Gain or loss would be reclassified into income only during the period in which the
hedged net investment was sold or liquidated. |
|
(6) |
|
Gain or loss on foreign exchange contracts not designated as hedges is offset by a
foreign currency transaction loss of less than $1 million and $39 million during the three
months ended Feb. 28, 2010, and Feb. 28, 2009, respectively, and a gain of $5 million and a
loss of $76 million during the six months ended Feb. 28, 2010, and Feb. 28, 2009,
respectively. |
Most of the companys outstanding foreign-currency derivatives are covered by International
Swap Dealers Association (ISDA) Master Agreements with the counterparties. There are no
requirements to post collateral under these agreements; however, should the companys credit rating
fall below a specified rating immediately following the merger of the company with another entity,
the counterparty may require all outstanding derivatives under the ISDA Master Agreement to be
settled immediately at current market value, which equals carrying value. Any foreign-currency
derivatives that are not covered by ISDA Master Agreements do not have credit-risk-related
contingent provisions. Most of the companys outstanding commodity derivatives are listed commodity
futures, and the company is required by the relevant commodity exchange to post collateral each day
to cover the change in the fair value of these futures. Any non-exchange traded commodity
derivatives are covered by the aforementioned ISDA Master Agreements and are subject to the same
credit-risk-related contingent provisions, as are the companys interest rate derivatives. The
aggregate fair value of all derivative instruments under ISDA Master Agreements that are in a
liability position on Feb. 28, 2010, and Feb. 28, 2009, is $32 million and $70 million,
respectively, which is the amount that would be required for settlement if the credit-risk-related
contingent provisions underlying these agreements were triggered.
Credit Risk Management
Monsanto invests its excess cash in deposits with major banks or money market funds throughout the
world in high-quality short-term debt instruments. Such investments are made only in instruments
issued or enhanced by high-quality institutions. As of Feb. 28, 2010, and Aug. 31, 2009, the
company had no financial instruments that represented a significant concentration of credit risk.
Limited amounts are invested in any single institution to minimize risk. The company has not
incurred any credit risk losses related to those investments.
The company sells a broad range of agricultural products to a diverse group of customers throughout
the world. In the United States, the company makes substantial sales to relatively few large
wholesale customers. The companys agricultural products business is highly seasonal, and it is
subject to weather conditions that affect commodity prices and seed yields. Credit limits, ongoing
credit evaluation, and account monitoring procedures are used to minimize the risk of loss.
Collateral is secured when it is deemed appropriate by the company.
Monsanto regularly evaluates its business practices to minimize its credit risk. During the six
months ended Feb. 28, 2010, and Aug. 31, 2009, the company engaged multiple banks in the United
States, Argentina, Brazil and Europe in the development of customer financing options that involve
direct bank financing of customer purchases. For further information on these programs, see Note 4
Customer Financing Programs.
24
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
NOTE 15. POSTRETIREMENT BENEFITS PENSIONS, HEALTH CARE AND OTHER
The majority of Monsantos employees are covered by noncontributory pension plans sponsored by the
company. The company also provides certain postretirement health care and life insurance benefits
for retired employees through insurance contracts. The companys net periodic benefit cost for
pension benefits, and health care and other postretirement benefits include the following
components:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, 2010 |
|
|
Three Months Ended Feb. 28, 2009 |
|
Pension Benefits |
|
|
|
|
|
Outside the |
|
|
|
|
|
|
|
|
|
|
Outside the |
|
|
|
|
(Dollars in millions) |
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
|
|
Service Cost for Benefits Earned During the Period |
|
$ |
12 |
|
|
$ |
1 |
|
|
$ |
13 |
|
|
$ |
12 |
|
|
$ |
1 |
|
|
$ |
13 |
|
Interest Cost on Benefit Obligation |
|
|
22 |
|
|
|
4 |
|
|
|
26 |
|
|
|
26 |
|
|
|
4 |
|
|
|
30 |
|
Assumed Return on Plan Assets |
|
|
(29 |
) |
|
|
(4 |
) |
|
|
(33 |
) |
|
|
(28 |
) |
|
|
(5 |
) |
|
|
(33 |
) |
Amortization of Unrecognized Net Loss |
|
|
13 |
|
|
|
1 |
|
|
|
14 |
|
|
|
9 |
|
|
|
2 |
|
|
|
11 |
|
Curtailment and Settlement Charge (Gain) |
|
|
2 |
|
|
|
(7 |
) |
|
|
(5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Periodic Benefit Cost (Gain) |
|
$ |
20 |
|
|
$ |
(5 |
) |
|
$ |
15 |
|
|
$ |
19 |
|
|
$ |
2 |
|
|
$ |
21 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended Feb. 28, 2010 |
|
|
Six Months Ended Feb. 28, 2009 |
|
Pension Benefits |
|
|
|
|
|
Outside the |
|
|
|
|
|
|
|
|
|
|
Outside the |
|
|
|
|
(Dollars in millions) |
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
U.S. |
|
|
U.S. |
|
|
Total |
|
|
|
|
Service Cost for Benefits Earned During the Period |
|
$ |
25 |
|
|
$ |
3 |
|
|
$ |
28 |
|
|
$ |
24 |
|
|
$ |
3 |
|
|
$ |
27 |
|
Interest Cost on Benefit Obligation |
|
|
47 |
|
|
|
8 |
|
|
|
55 |
|
|
|
53 |
|
|
|
8 |
|
|
|
61 |
|
Assumed Return on Plan Assets |
|
|
(61 |
) |
|
|
(8 |
) |
|
|
(69 |
) |
|
|
(58 |
) |
|
|
(9 |
) |
|
|
(67 |
) |
Amortization of Unrecognized Net Loss |
|
|
27 |
|
|
|
2 |
|
|
|
29 |
|
|
|
19 |
|
|
|
2 |
|
|
|
21 |
|
Curtailment and Settlement Charge (Gain) |
|
|
2 |
|
|
|
(7 |
) |
|
|
(5 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Net Periodic Benefit Cost (Gain) |
|
$ |
40 |
|
|
$ |
(2 |
) |
|
$ |
38 |
|
|
$ |
38 |
|
|
$ |
4 |
|
|
$ |
42 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Health Care and Other Postretirement Benefits |
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
Service Cost for Benefits Earned During the Period |
|
$ |
2 |
|
|
$ |
3 |
|
|
$ |
5 |
|
|
$ |
6 |
|
Interest Cost on Benefit Obligation |
|
|
2 |
|
|
|
4 |
|
|
|
6 |
|
|
|
9 |
|
Amortization of Unrecognized Net Gain |
|
|
(2 |
) |
|
|
(4 |
) |
|
|
(6 |
) |
|
|
(8 |
) |
|
|
|
Total Net Periodic Benefit Cost |
|
$ |
2 |
|
|
$ |
3 |
|
|
$ |
5 |
|
|
$ |
7 |
|
|
|
|
Monsanto contributed $75 million and $30 million to its U.S. qualified plan and $11 million
and $4 million to plans outside the United States in each of the six month periods ended Feb. 28,
2010, and Feb. 28, 2009, respectively. As of Feb. 28, 2010, management does not expect to make
additional contributions to the companys U.S. qualified plan in
fiscal 2010. Pension plan funding regulations include conditions that allow a plans credit balance created as a result of
prior years contributions in excess of the required minimum to be used to satisfy current year
contributions. Discretionary contributions made by the company previously have created a credit
balance and the company expects to use a portion of it in lieu of making additional fiscal year
2010 contributions. As of Feb. 28, 2010, management expects to make additional contributions of
approximately $11 million to the companys pension plans outside the United States in fiscal year
2010.
Employee Savings Plan
The Monsanto leveraged employee stock ownership plan (Monsanto ESOP) debt was restructured in
November 2008 to level out the future allocation of stock thereunder in an impartial manner
intended to ensure equitable treatment for and generally to be in the best interests of current and
future plan participants consistent with the level of benefits that Monsanto intended for the plan
to provide to participants. To that end, the terms of the restructuring were determined pursuant to
an arms length negotiation between Monsanto and an independent trust company serving as fiduciary
for the plan for this restructuring. In
25
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
this role, the independent fiduciary determined that the restructuring, including certain financial
commitments and enhancements that were made or will be made in the future by Monsanto to benefit
participants and beneficiaries of the plan, was completed in accordance with the best interests of
plan participants. A liability of $54 million and $52 million is due to the Monsanto ESOP from the
company and is included in other liabilities on the Condensed Statements of Financial Position as
of Feb. 28, 2010, and Aug. 31, 2009, respectively, related to this restructuring and the 2004 ESOP
enhancement.
NOTE 16. STOCK-BASED COMPENSATION PLANS
The following table shows total stock-based compensation expense included in the Statements of
Consolidated Operations for the three and six months ended Feb. 28, 2010, and Feb. 28, 2009.
Stock-based compensation cost capitalized in inventory was $7 million as of Feb. 28, 2010, and Aug.
31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
Cost of Goods Sold |
|
$ |
4 |
|
|
$ |
4 |
|
|
$ |
8 |
|
|
$ |
8 |
|
Selling, General and Administrative Expenses |
|
|
17 |
|
|
|
19 |
|
|
|
32 |
|
|
|
35 |
|
Research and Development Expenses |
|
|
7 |
|
|
|
6 |
|
|
|
12 |
|
|
|
12 |
|
|
|
|
Pre-Tax Stock-Based Compensation Expense |
|
|
28 |
|
|
|
29 |
|
|
|
52 |
|
|
|
55 |
|
Income Tax Benefit |
|
|
(10 |
) |
|
|
(10 |
) |
|
|
(18 |
) |
|
|
(19 |
) |
|
|
|
Net Stock-Based Compensation Expense |
|
$ |
18 |
|
|
$ |
19 |
|
|
$ |
34 |
|
|
$ |
36 |
|
|
|
|
During the six months ended Feb. 28, 2010, Monsanto granted 3,296,890 stock options and
491,675 restricted stock units to employees under the Monsanto Company Long-Term Incentive Plan
(LTIP), as amended, and the Monsanto Company 2005 Long-Term Incentive Plan (2005 LTIP). No
restricted stock awards were granted under the LTIP or the 2005 LTIP during the six months ended
Feb. 28, 2010. In addition, during the six months ended Feb. 28, 2010, 17,970 shares of deferred
stock and 1,190 shares of restricted stock were granted to directors under the Monsanto
Non-Employee Director Equity Incentive Compensation Plan (Director Plan).
The weighted-average grant-date fair value of non-qualified stock options granted during the six
months ended Feb. 28, 2010, was $24.08 per share. Pre-tax unrecognized compensation expense for
stock options, net of estimated forfeitures, was $104 million as of Feb. 28, 2010, and will be
recognized as expense over a weighted-average period of 2.2 years.
The weighted-average grant-date fair value of restricted stock units granted during the six months
ended Feb. 28, 2010, was $72.29 per share. Pre-tax unrecognized compensation expense, net of
estimated forfeitures, for nonvested restricted stock and restricted stock units was $1 million and
$92 million, respectively, as of Feb. 28, 2010, which will be recognized as expense over the
weighted-average remaining requisite service periods. The weighted-average remaining requisite
service periods for nonvested restricted stock and restricted stock units were 1.6 years and 2.8
years, respectively, as of Feb. 28, 2010. The weighted-average grant-date fair value of directors
deferred stock and directors restricted stock granted during the six months ended Feb. 28, 2010,
was $81.94 per share. Pre-tax unrecognized compensation expense for awards granted under the
Director Plan was $1 million as of Feb. 28, 2010, and will be recognized as expense over a
weighted-average period of one year.
NOTE 17. COMPREHENSIVE INCOME (LOSS)
Comprehensive
income (loss) includes all nonshareowner changes in equity and
consists of net income, foreign currency translation adjustments, net unrealized losses on available-for-sale securities, postretirement benefit plan activity, and net
accumulated
26
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
derivative gains and losses on cash flow hedges not yet realized. Information regarding comprehensive income is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
Comprehensive Income |
|
$ |
700 |
|
|
$ |
947 |
|
|
$ |
940 |
|
|
$ |
690 |
|
|
|
|
The components of accumulated other comprehensive loss are as follows:
|
|
|
|
|
|
|
|
|
|
|
As of Feb. 28, |
|
|
As of Aug. 31, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
|
|
Accumulated Foreign Currency Translation Adjustments |
|
$ |
(158 |
) |
|
$ |
(141 |
) |
Net Unrealized Loss on Investments, Net of Tax |
|
|
(3 |
) |
|
|
(6 |
) |
Net Accumulated Derivative Loss, Net of Tax |
|
|
(39 |
) |
|
|
(101 |
) |
Postretirement Benefit Plan Activity, Net of Tax |
|
|
(474 |
) |
|
|
(496 |
) |
|
|
|
Accumulated Other Comprehensive Loss |
|
$ |
(674 |
) |
|
$ |
(744 |
) |
|
|
|
NOTE 18. EARNINGS PER SHARE
Basic earnings per share (EPS) was computed using the weighted-average number of common shares
outstanding during the period shown in the table below. For the three months and six months ended
Feb. 28, 2010, and Feb. 28, 2009, diluted EPS was computed taking into account the effect of
dilutive potential common shares, as shown in the table below. Potential common shares consist
primarily of stock options, restricted stock, restricted stock units and directors deferred shares
calculated using the treasury stock method and are excluded if their effect is antidilutive.
Approximately 8.1 million and 5 million stock options were excluded from the computations of
dilutive potential common shares as they were antidilutive for the three and six months ended Feb.
28, 2010, and Feb. 28, 2009, respectively. Of those antidilutive options, approximately 5 million
stock options were excluded from the computations of dilutive potential common shares for the three
and six months ended Feb. 28, 2010, and Feb. 28, 2009, as their exercise prices were greater than
the average market price of common shares for the period.
Effective Sept. 1, 2009, the company retrospectively adopted a FASB-issued standard that requires
unvested share-based payment awards that contain rights to receive non-forfeitable dividends or
dividend equivalents to be included in the two-class method of computing earnings per share as
described in the Earnings Per Share topic of the ASC. The adoption of this standard increased the
weighted average number of basic and diluted shares by 0.6 million and 0.3 million, respectively,
for the three months ended Feb. 28, 2009, and by 0.7 million and 0.2 million, respectively, for the
six months ended Feb. 28, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
Six Months Ended Feb. 28, |
|
|
2010 |
|
2009 |
|
2010 |
|
2009 |
|
|
|
Weighted-Average Number of Common Shares
|
|
|
545.8 |
|
|
|
547.2 |
|
|
|
545.7 |
|
|
|
548.0 |
|
Dilutive Potential Common Shares
|
|
|
7.6 |
|
|
|
8.3 |
|
|
|
7.7 |
|
|
|
8.5 |
|
|
|
|
27
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
NOTE 19. SUPPLEMENTAL CASH FLOW INFORMATION
Cash payments for interest and taxes were as follows:
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
Interest |
|
$ |
81 |
|
|
$ |
55 |
|
Taxes |
|
|
160 |
|
|
|
105 |
|
|
During the first half of fiscal 2010 and 2009, the company recorded the following noncash
investing and financing transaction: In second quarter 2010 and 2009, the board of directors
declared a dividend which was payable in third quarter 2010 and 2009, respectively. As of Feb. 28,
2010, and Feb. 28, 2009, a dividend payable of $145 million was recorded.
NOTE 20. COMMITMENTS AND CONTINGENCIES
Environmental and Litigation Liabilities: Monsanto is involved in environmental remediation and
legal proceedings related to its current business and, pursuant to its indemnification obligations,
related to Pharmacias former chemical and agricultural businesses. In addition, Monsanto has
liabilities established for various product claims. With respect to certain of these proceedings,
Monsanto has a liability recorded of $281 million and $262 million as of Feb. 28, 2010, and Aug.
31, 2009, respectively, for the estimated contingent liabilities. Information regarding the
environmental liabilities appears in Monsantos Report on Form 10-K for the fiscal year ended Aug.
31, 2009.
Litigation: The above liability includes amounts related to certain third-party litigation with
respect to Monsantos business, as well as tort litigation related to Pharmacias former chemical
business, including lawsuits involving polychlorinated biphenyls (PCBs), dioxins, and other
chemical and premises liability litigation. Additional matters that are not reflected in the
liability may arise in the future, and Monsanto may manage, settle, or pay judgments or damages
with respect thereto in order to mitigate contesting potential liability. Following is a
description of one of the more significant litigation matters reflected in the liability.
|
|
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2009, and
Monsantos Report on Form 10-Q for the quarterly period ended Nov. 30, 2009, on Dec. 17, 2004,
15 plaintiffs filed a purported class action lawsuit, styled Virdie Allen, et al. v. Monsanto,
et al., in the Putnam County, West Virginia, state court against Monsanto, Pharmacia and seven
other defendants. Monsanto is named as the successor in interest to the liabilities of
Pharmacia. The alleged class consists of all current and former residents, workers, and
students who, between 1949 and the present, were allegedly exposed to dioxins/furans
contamination in counties surrounding Nitro, West Virginia. The complaint alleges that the
source of the contamination is a chemical plant in Nitro, formerly owned and operated by
Pharmacia and later by Flexsys, a joint venture between Solutia and Akzo Nobel Chemicals, Inc.
(Akzo Nobel). Akzo Nobel and Flexsys were named defendants in the case but Solutia was not,
due to its then pending bankruptcy proceeding. The suit seeks damages for property cleanup
costs, loss of real estate value, funds to test property for contamination levels, funds to
test for human exposure, and future medical monitoring costs. The complaint also seeks an
injunction against further contamination and punitive damages. Monsanto has agreed to
indemnify and defend Akzo Nobel and the Flexsys defendant group. The class action
certification hearing was held on Oct. 29, 2007. On Jan. 8, 2008, the trial court issued an
order certifying the Carter and Allen (now Zina G. Bibb et al. v. Monsanto et al., because
Bibb replaced Allen as class representative) cases as class action matters. The court has set
a trial date of April 4, 2011, for the Bibb class action. |
|
|
|
In October 2007 and November 2009, a total of approximately 200 separate, single plaintiff civil
actions were filed in Putnam County, West Virginia, against Monsanto, Pharmacia, Akzo Nobel (and
several of its affiliates), Flexsys |
28
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
|
|
America Co. (and several of its affiliates), Solutia, and Apogee Coal Company, LLC. These cases
allege personal injury occasioned by exposure to dioxin generated by the Nitro Plant during
production of 2,4,5 T (1949-1969) and thereafter. Monsanto has agreed to accept the tenders of
defense in the matters by Pharmacia, Solutia, Akzo Nobel and Flexsys America under a reservation
of rights. |
Including litigation reflected in the liability, Monsanto is involved in various legal proceedings
that arise in the ordinary course of its business or pursuant to Monsantos indemnification
obligations to Pharmacia, as well as proceedings that management has considered to be material
under SEC regulations. Some of the lawsuits seek damages in very large amounts, or seek to restrict
the companys business activities. Monsanto believes that it has meritorious legal arguments and
will continue to represent its interests vigorously in all of the proceedings that it is defending
or prosecuting. Although the ultimate liabilities resulting from such proceedings, or the
proceedings reflected in the above liability, may be significant to profitability in the period
recognized, management does not anticipate they will have a material adverse effect on Monsantos
consolidated financial position or liquidity. A description of one of these proceedings appears
below.
|
|
As described in Monsantos Report on Form 10-K for the fiscal year ended Aug. 31, 2009, and
Monsantos Report on Form 10-Q for the quarterly period ended Nov. 30, 2009, on June 23, 2004,
two former employees of Monsanto and Pharmacia filed a purported class action lawsuit in the
U.S. District Court for the Southern District of Illinois against Monsanto and the Monsanto
Company Pension Plan, which is referred to as the Pension Plan. The suit claims that the
Pension Plan has violated the age discrimination and other rules under the Employee Retirement
Income Security Act of 1974 from Jan. 1, 1997 (when the Pension Plan was sponsored by
Pharmacia, then known as Monsanto Company) and continuing to the present. In January 2006, a
separate group of former employees of Pharmacia filed a similar purported class action lawsuit
in the U.S. District Court for the Southern District of Illinois against Pharmacia, the
Pharmacia Cash Balance Plan, and other defendants. On July 7, 2006, the plaintiffs amended
their lawsuit to add Monsanto and the Pension Plan as additional defendants. On Sept. 1, 2006,
the Court consolidated these lawsuits with two purported class action lawsuits also pending in
the same Court against the Solutia Company Pension Plan, under Walker v. Monsanto, the first
filed case. The court conducted a class certification hearing on Sept. 12, 2007. Prior to the
hearing, all parties agreed the case should proceed as a class action and also agreed on a
definition of the respective classes. The classes were certified by court order on May 22,
2008. On July 11, 2008, all parties filed dispositive motions on the issue of liability, which
motions were heard by the court on May 6, 2009. On June 11, 2009, the Court granted summary
judgment in favor of Monsanto and the other defendants on the age discrimination claims. The
Court granted summary judgment in favor of the plaintiffs on a separate claim regarding
post-termination interest, which was subsequently settled for an immaterial amount. The Court
entered judgment on the entire case on Sept. 29, 2009. On Oct. 27, 2009, the plaintiffs filed
a notice of appeal of the summary judgment order on the age discrimination claims.
The Seventh Circuit Court of Appeals has scheduled oral argument in
this case for April 20, 2010. |
Guarantees: Disclosures regarding the guarantees Monsanto provides for certain customer loans in
the United States, Brazil, Europe, and Argentina can be found in Note 4 Customer Financing
Programs of this Form 10-Q. Except as described in that note, there have been no significant
changes to guarantees made by Monsanto since Aug. 31, 2009. Disclosures regarding these guarantees
made by Monsanto can be found in Note 25 Commitments and Contingencies of the notes to the
consolidated financial statements contained in Monsantos Report on Form 10-K for the fiscal year
ended Aug. 31, 2009.
NOTE 21. SEGMENT INFORMATION
Monsanto conducts its worldwide operations through global businesses, which are aggregated into
reportable segments based on similarity of products, production processes, customers, distribution
methods and economic characteristics. The operating segments are aggregated into two reportable
segments: Seeds and Genomics and Agricultural Productivity. The Seeds and Genomics segment consists
of the global seeds and related traits businesses and biotechnology platforms. Within the Seeds and
Genomics segment, Monsantos significant operating segments are corn seed and traits, soybean seed
and traits, cotton seed and traits, vegetable seeds and all other crops seeds and traits. The wheat
and sugarcane businesses acquired in fourth and second quarter 2009, respectively, are included in
the all other crops seeds and traits operating segment. The Agricultural
29
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
Productivity segment consists of the crop protection products and lawn-and-garden herbicide
products. The Dairy business, which was previously included in the Agricultural Productivity
segment, was divested in fiscal year 2009 and is included in discontinued operations. Within the
Agricultural Productivity segment, the significant operating segments are ROUNDUP and other
glyphosate-based products and all other agricultural products. EBIT is defined as earnings (loss)
before interest and taxes and is the primary operating performance measure for the two business
segments. EBIT is useful to management in demonstrating the operational profitability of the
segments by excluding interest and taxes, which are generally accounted for across the entire
company on a consolidated basis. Sales between segments were not significant. Certain selling,
general and administrative expenses are allocated between segments based on activity. Based on the
Agricultural Productivity segments decreasing contribution to total Monsanto operations, the
allocation percentages were changed at the beginning of fiscal year 2010.
Data for the Seeds and Genomics and Agricultural Productivity reportable segments, as well as for
Monsantos significant operating segments, is presented in the table that follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
Net Sales(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corn seed and traits |
|
$ |
2,247 |
|
|
$ |
2,078 |
|
|
$ |
2,816 |
|
|
$ |
2,706 |
|
Soybean seed and traits |
|
|
633 |
|
|
|
615 |
|
|
|
834 |
|
|
|
827 |
|
Cotton seed and traits |
|
|
34 |
|
|
|
33 |
|
|
|
93 |
|
|
|
80 |
|
Vegetable seeds |
|
|
223 |
|
|
|
209 |
|
|
|
396 |
|
|
|
366 |
|
All other crops seeds and traits |
|
|
111 |
|
|
|
107 |
|
|
|
140 |
|
|
|
162 |
|
|
|
|
Total seeds and genomics |
|
$ |
3,248 |
|
|
$ |
3,042 |
|
|
$ |
4,279 |
|
|
$ |
4,141 |
|
|
|
|
ROUNDUP and other glyphosate-based herbicides |
|
$ |
465 |
|
|
$ |
776 |
|
|
$ |
974 |
|
|
$ |
2,135 |
|
All other agricultural products |
|
|
177 |
|
|
|
217 |
|
|
|
334 |
|
|
|
408 |
|
|
|
|
Total agricultural productivity |
|
$ |
642 |
|
|
$ |
993 |
|
|
$ |
1,308 |
|
|
$ |
2,543 |
|
|
|
|
Total |
|
$ |
3,890 |
|
|
$ |
4,035 |
|
|
$ |
5,587 |
|
|
$ |
6,684 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
EBIT(2)(3)(4) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Seeds and genomics |
|
$ |
1,362 |
|
|
$ |
1,212 |
|
|
$ |
1,305 |
|
|
$ |
1,277 |
|
Agricultural productivity |
|
|
(87 |
) |
|
|
326 |
|
|
|
(53 |
) |
|
|
999 |
|
|
|
|
Total |
|
$ |
1,275 |
|
|
$ |
1,538 |
|
|
$ |
1,252 |
|
|
$ |
2,276 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and Amortization Expense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Seeds and genomics |
|
$ |
114 |
|
|
$ |
105 |
|
|
$ |
224 |
|
|
$ |
208 |
|
Agricultural productivity |
|
|
36 |
|
|
|
30 |
|
|
|
70 |
|
|
|
62 |
|
|
|
|
Total |
|
$ |
150 |
|
|
$ |
135 |
|
|
$ |
294 |
|
|
$ |
270 |
|
|
|
|
|
|
|
(1) |
|
Represents net sales from continuing operations. |
|
(2) |
|
EBIT is defined as earnings (loss) before interest and taxes; see the following
table for reconciliation. Earnings (loss) is intended to mean net income (loss) as presented
in the Statements of Consolidated Operations under generally accepted accounting principles.
EBIT is the primary operating performance measure for the two business segments. |
|
(3) |
|
Agricultural Productivity EBIT includes income from discontinued operations of $1
million for the three months ended Feb. 28, 2009, and $5 million and $19 million for the six
months ended Feb. 28, 2010, and Feb. 28, 2009, respectively. |
|
(4) |
|
EBIT includes restructuring charges for three and six months ended Feb. 28, 2010.
See Note 5 Restructuring for additional information. |
30
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
NOTES
TO THE CONSOLIDATED FINANCIAL STATEMENTS UNAUDITED
(continued)
A reconciliation of EBIT to net income for each period follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
2010 |
|
|
2009 |
|
|
|
|
EBIT(1) |
|
$ |
1,275 |
|
|
$ |
1,538 |
|
|
$ |
1,252 |
|
|
$ |
2,276 |
|
Interest Expense Net |
|
|
27 |
|
|
|
8 |
|
|
|
55 |
|
|
|
6 |
|
Income Tax Provision(2) |
|
|
361 |
|
|
|
438 |
|
|
|
329 |
|
|
|
622 |
|
|
|
|
Net Income Attributable to Monsanto Company |
|
$ |
887 |
|
|
$ |
1,092 |
|
|
$ |
868 |
|
|
$ |
1,648 |
|
|
|
|
|
|
|
(1) |
|
Includes the income from operations of discontinued businesses and pre-tax
noncontrolling interest. |
|
(2) |
|
Includes the income tax provision from continuing operations, the income tax
(benefit) provision on noncontrolling interest and the income tax provision on discontinued
operations. |
NOTE 22. DISCONTINUED OPERATIONS
Dairy Business Divestiture: During fourth quarter 2008, the company determined that the Dairy
business was no longer consistent with its strategic business objectives, and thus entered into an
agreement to sell the majority of the Dairy business assets (excluding cash, trade receivables and
certain property) to Eli Lilly and Company for $300 million, plus additional contingent
consideration. The contingent consideration is a 10 year earn-out with potential annual payments
being earned by Monsanto if certain revenue levels are exceeded. On Oct. 1, 2008, Monsanto
consummated the sale to Eli Lilly after receiving approval from the appropriate regulatory
agencies. As a result, the Dairy business has been segregated from continuing operations and
presented as discontinued operations. The Dairy business was previously reported as a part of the
Agricultural Productivity segment. During the six months ended Feb. 28, 2010, income from
operations of discontinued businesses included a $5 million pre-tax gain related to the sale of
assets. During the six months ended Feb. 28, 2009, income from operations of discontinued
businesses included an $11 million pre-tax gain related to the sale.
31
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
ITEM 2. MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Background
Monsanto Company, along with its subsidiaries, is a leading global provider of agricultural
products for farmers. Our seeds, biotechnology trait products, and herbicides provide farmers with
solutions that improve productivity, reduce the costs of farming, and produce better foods for
consumers and better feed for animals.
We manage our business in two segments: Seeds and Genomics and Agricultural Productivity. Through
our Seeds and Genomics segment, we produce leading seed brands, including DEKALB, ASGROW,
DELTAPINE, SEMINIS and DE RUITER, and we develop biotechnology traits that assist farmers in
controlling insects and weeds. We also provide other seed companies with genetic material and
biotechnology traits for their seed brands. Through our Agricultural Productivity segment, we
manufacture ROUNDUP brand herbicides and other herbicides and provide lawn-and-garden herbicide
products for the residential market.
In the fourth quarter of 2008, we entered into an agreement to divest the Dairy business. This
transaction was consummated on Oct. 1, 2008. As a result, financial statements have been prepared
in compliance with the provisions of the Property, Plant and Equipment topic of the Financial
Accounting Standards Board (FASB) Accounting Standards Codification (ASC). Accordingly, the
Statements of Consolidated Operations have been conformed to this presentation. The Dairy business
was previously reported as part of the Agricultural Productivity segment. See Note 22
Discontinued Operations for further details.
Managements Discussion and Analysis of Financial Condition and Results of Operations (MD&A) should
be read in conjunction with Monsantos consolidated financial statements and the accompanying
notes. This Report on Form 10-Q should also be read in conjunction with Monsantos Report on Form
10-K for the fiscal year ended Aug. 31, 2009. Financial information for the first six months of
fiscal year 2010 should not be annualized because of the seasonality of our business. The notes to
the consolidated financial statements referred to throughout this MD&A are included in Part I
Item 1 Financial Statements of this Report on Form 10-Q. Unless otherwise indicated,
Monsanto, the company, we, our and us are used interchangeably to refer to Monsanto
Company or to Monsanto Company and its consolidated subsidiaries, as appropriate to the context.
Unless otherwise indicated, earnings (loss) per share and per share mean diluted earnings
(loss) per share. Unless otherwise noted, all amounts and analyses are based on continuing
operations. Unless otherwise indicated, trademarks owned or licensed by Monsanto or its
subsidiaries are shown in all capital letters. Unless otherwise indicated, references to ROUNDUP
herbicides mean ROUNDUP branded herbicides, excluding all lawn-and-garden herbicides, and
references to ROUNDUP and other glyphosate-based herbicides exclude all lawn-and-garden
herbicides.
Non-GAAP Financial Measures
MD&A includes financial information prepared in accordance with U.S. generally accepted accounting
principles (GAAP), as well as two other financial measures, EBIT and free cash flow, that are
considered non-GAAP financial measures. Generally, a non-GAAP financial measure is a numerical
measure of a companys financial performance, financial position or cash flows that exclude (or
include) amounts that are included in (or excluded from) the most directly comparable measure
calculated and presented in accordance with GAAP. The presentation of EBIT and free cash flow
information is intended to supplement investors understanding of our operating performance and
liquidity. Our EBIT and free cash flow measures may not be comparable to other companies EBIT and
free cash flow measures. Furthermore, these measures are not intended to replace net income, cash
flows, financial position, or comprehensive income, as determined in accordance with U.S. GAAP.
EBIT is defined as earnings (loss) before interest and taxes. Earnings is intended to mean net
income as presented in the Statements of Consolidated Operations under GAAP. EBIT is the primary
operating performance measure for our two business segments. We believe that EBIT is useful to
investors and management to demonstrate the operational profitability of our segments by excluding
interest and taxes, which are generally accounted for across the entire company on a consolidated
basis. EBIT is also one of the measures used by Monsanto management to determine resource
allocations within the company. See Note 21 Segment Information for a reconciliation of EBIT to
net income for the three and six months ended Feb. 28, 2010, and Feb. 28, 2009.
32
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
We also provide information regarding free cash flow, an important liquidity measure for Monsanto.
We define free cash flow as the total of net cash provided or required by operating activities and
provided or required by investing activities. We believe that free cash flow is useful to investors
and management as a measure of the ability of our business to generate cash. This cash can be used
to meet business needs and obligations, to reinvest in the company for future growth, or to return
to our shareowners through dividend payments or share repurchases. Free cash flow is also used by
management as one of the performance measures in determining incentive compensation. See the
Financial Condition, Liquidity, and Capital Resources Cash Flow section of MD&A for a
reconciliation of free cash flow to net cash provided by operating activities and net cash required
by investing activities on the Statements of Consolidated Cash Flows.
Executive Summary
Consolidated Operating Results Net sales decreased $145 million, or four percent, in the
three-month comparison and $1,097 million, or 16 percent, in the six-month comparison. This decline
was primarily a result of decreased sales of ROUNDUP and other glyphosate-based herbicides in the
United States, Brazil and Europe. Net income in first half 2010 was $1.57 per share, compared with
$2.96 per share in first half 2009.
Financial Condition, Liquidity, and Capital Resources In first half 2010, net cash provided by
operating activities was $256 million, compared with $1,500 million in the prior-year period. Net
cash required by investing activities was $345 million in first half of 2010 compared with $359
million in first half of 2009. Free cash flow was a negative $89 million for the six months ended
Feb. 28, 2010, compared with a positive $1,141 million for the six months ended Feb. 28, 2009. This
decrease is primarily because of lower glyphosate sales in 2010 compared to 2009 reducing net
income, the timing of collections, lower commodity prices, reduced market funding and the sale of
the Dairy business in the prior year.
Outlook We plan to continue to improve our products in order to maintain market leadership and to
support near-term performance. We are focused on applying innovation and technology to make our
farmer customers more productive and profitable by protecting yields and improving the ways they
can produce food, fiber and feed. We use the tools of modern biology to make seeds easier to grow,
to allow farmers to do more with fewer resources, and to produce healthier foods for consumers. Our
current research and development (R&D) strategy and commercial priorities are focused on bringing
our farmer customers even more choices of seed offerings through second-generation traits that
deliver multiple solutions in one seed (stacking) and on developing new pipeline products. Our
capabilities in biotechnology and breeding research are generating a rich product pipeline that is
expected to drive long-term growth. The viability of our product pipeline depends in part on the
speed of regulatory approvals globally and on continued patent and legal rights to offer our
products.
We plan to grow our vegetable seeds business. We have applied our molecular breeding and marker
capabilities to our library of vegetable germplasm. In the future, we will continue to focus on
accelerating the potential growth of this business and executing our business plans.
ROUNDUP herbicides remain the largest crop protection brand globally. Previous periods had seen
increasing global demand and higher raw material costs in the glyphosate market in a time of tight
supply, causing a period of higher prices. More recently the significant supply of lower priced
generics has caused increased competitive pressure in the market and a decline in the business due
to our previously announced price reduction. We are focused on managing the costs associated with
our agricultural chemistry business as that sector matures globally.
See the Outlook section of MD&A for a more detailed discussion of some of the opportunities and
risks we have identified for our business. For additional information related to the outlook for
Monsanto, see Caution Regarding Forward-Looking Statements at the beginning of this Report on
Form 10-Q, Part II Item 1A Risk Factors below and Part I Item 1A of our Report on Form 10-K
for the fiscal year ended Aug. 31, 2009.
33
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
|
Six Months Ended Feb. 28, |
|
(Dollars in millions, except per share amounts) |
|
2010 |
|
|
2009 |
|
|
Change |
|
|
2010 |
|
|
2009 |
|
|
Change |
|
|
|
|
Net Sales |
|
$ |
3,890 |
|
|
$ |
4,035 |
|
|
|
(4 |
)% |
|
$ |
5,587 |
|
|
$ |
6,684 |
|
|
|
(16 |
)% |
Gross Profit |
|
|
2,099 |
|
|
|
2,521 |
|
|
|
(17 |
)% |
|
|
2,838 |
|
|
|
4,071 |
|
|
|
(30 |
)% |
Operating Expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administrative expenses |
|
|
512 |
|
|
|
522 |
|
|
|
(2 |
)% |
|
|
1,008 |
|
|
|
1,072 |
|
|
|
(6 |
)% |
Research and development expenses |
|
|
279 |
|
|
|
265 |
|
|
|
5 |
% |
|
|
546 |
|
|
|
517 |
|
|
|
6 |
% |
Acquired in-process research and development |
|
|
|
|
|
|
162 |
|
|
|
(100 |
)% |
|
|
|
|
|
|
162 |
|
|
|
(100 |
)% |
Restructuring charges, net |
|
|
30 |
|
|
|
|
|
|
NM |
|
|
44 |
|
|
|
|
|
|
NM |
|
|
|
Total Operating Expenses |
|
|
821 |
|
|
|
949 |
|
|
|
(13 |
)% |
|
|
1,598 |
|
|
|
1,751 |
|
|
|
(9 |
)% |
|
|
|
Income from Operations |
|
|
1,278 |
|
|
|
1,572 |
|
|
|
(19 |
)% |
|
|
1,240 |
|
|
|
2,320 |
|
|
|
(47 |
)% |
Interest expense |
|
|
41 |
|
|
|
26 |
|
|
|
58 |
% |
|
|
80 |
|
|
|
49 |
|
|
|
63 |
% |
Interest income |
|
|
(14 |
) |
|
|
(18 |
) |
|
|
(22 |
)% |
|
|
(25 |
) |
|
|
(43 |
) |
|
|
(42 |
)% |
Other expense (income) net |
|
|
2 |
|
|
|
32 |
|
|
|
(94 |
)% |
|
|
(10 |
) |
|
|
58 |
|
|
|
(117 |
)% |
|
|
|
Income from Continuing Operations Before Income Taxes |
|
|
1,249 |
|
|
|
1,532 |
|
|
|
(18 |
)% |
|
|
1,195 |
|
|
|
2,256 |
|
|
|
(47 |
)% |
Income tax provision |
|
|
360 |
|
|
|
440 |
|
|
|
(18 |
)% |
|
|
330 |
|
|
|
616 |
|
|
|
(46 |
)% |
|
|
|
Income from Continuing Operations Including Portion
Attributable to Noncontrolling Interest |
|
|
889 |
|
|
|
1,092 |
|
|
|
(19 |
)% |
|
|
865 |
|
|
|
1,640 |
|
|
|
(47 |
)% |
|
|
|
Discontinued Operations: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from operations of discontinued businesses |
|
|
|
|
|
|
1 |
|
|
|
(100 |
)% |
|
|
5 |
|
|
|
19 |
|
|
|
(74 |
)% |
Income tax provision |
|
|
|
|
|
|
|
|
|
NM |
|
|
|
|
|
|
8 |
|
|
|
(100 |
)% |
|
|
|
Income on Discontinued Operations |
|
|
|
|
|
|
1 |
|
|
|
(100 |
)% |
|
|
5 |
|
|
|
11 |
|
|
|
(55 |
)% |
|
|
|
Net Income |
|
$ |
889 |
|
|
$ |
1,093 |
|
|
|
(19 |
)% |
|
$ |
870 |
|
|
$ |
1,651 |
|
|
|
(47 |
)% |
|
|
|
Less: Net income attributable to noncontrolling interest |
|
|
2 |
|
|
|
1 |
|
|
|
100 |
% |
|
|
2 |
|
|
|
3 |
|
|
|
(33 |
)% |
|
|
|
Net Income Attributable to Monsanto Company |
|
$ |
887 |
|
|
$ |
1,092 |
|
|
|
(19 |
)% |
|
$ |
868 |
|
|
$ |
1,648 |
|
|
|
(47 |
)% |
|
|
|
Diluted Earnings per Share Attributable to Monsanto Company: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income from continuing operations |
|
$ |
1.60 |
|
|
$ |
1.96 |
|
|
|
(18 |
)% |
|
$ |
1.56 |
|
|
$ |
2.94 |
|
|
|
(47 |
)% |
Income on discontinued operations |
|
|
|
|
|
|
0.01 |
|
|
NM |
|
|
0.01 |
|
|
|
0.02 |
|
|
|
(50 |
)% |
|
|
|
Net Income |
|
$ |
1.60 |
|
|
$ |
1.97 |
|
|
|
(19 |
)% |
|
$ |
1.57 |
|
|
$ |
2.96 |
|
|
|
(47 |
)% |
|
|
|
NM = Not Meaningful |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effective Tax Rate |
|
|
29 |
% |
|
|
29 |
% |
|
|
|
|
|
|
28 |
% |
|
|
27 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Comparison as a Percent of Net Sales: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
|
|
54 |
% |
|
|
62 |
% |
|
|
|
|
|
|
51 |
% |
|
|
61 |
% |
|
|
|
|
Selling, general and administrative expenses |
|
|
13 |
% |
|
|
13 |
% |
|
|
|
|
|
|
18 |
% |
|
|
16 |
% |
|
|
|
|
Research and development expenses (excluding acquired IPR&D) |
|
|
7 |
% |
|
|
7 |
% |
|
|
|
|
|
|
10 |
% |
|
|
8 |
% |
|
|
|
|
Total operating expenses |
|
|
21 |
% |
|
|
24 |
% |
|
|
|
|
|
|
29 |
% |
|
|
26 |
% |
|
|
|
|
Income from continuing operations before income taxes |
|
|
32 |
% |
|
|
38 |
% |
|
|
|
|
|
|
21 |
% |
|
|
34 |
% |
|
|
|
|
Net income attributable to Monsanto Company |
|
|
23 |
% |
|
|
27 |
% |
|
|
|
|
|
|
16 |
% |
|
|
25 |
% |
|
|
|
|
Second Quarter Fiscal Year 2010
The following explanations discuss the significant components of our results of operations
that affected the quarter-to-quarter comparison of our second quarter income from continuing
operations:
Net sales decreased four percent in second quarter 2010 from the same quarter a year ago.
Our Seeds and Genomics segment net sales increased seven percent, and our Agricultural Productivity
segment net sales declined 35 percent. The following table presents the percentage changes in
second quarter 2010 worldwide net sales by segment compared with net sales in the
34
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
prior-year quarter, including the effect volume, price, currency and acquisitions had on these
percentage changes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second Quarter 2010 Percentage Change in Net Sales vs. Second Quarter 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of |
|
|
|
|
|
|
Volume |
|
|
Price |
|
|
Currency |
|
|
Subtotal |
|
|
Acquisitions(1) |
|
|
Net Change |
|
|
|
|
Seeds and Genomics Segment |
|
|
1 |
% |
|
|
3 |
% |
|
|
3 |
% |
|
|
7 |
% |
|
|
|
|
|
|
7 |
% |
Agricultural Productivity
Segment |
|
|
18 |
% |
|
|
(55 |
)% |
|
|
2 |
% |
|
|
(35 |
)% |
|
|
|
|
|
|
(35 |
)% |
Total Monsanto Company |
|
|
5 |
% |
|
|
(11 |
)% |
|
|
2 |
% |
|
|
(4 |
)% |
|
|
|
|
|
|
(4 |
)% |
|
|
|
|
(1) |
|
See Note 3 Business Combinations and Financial Condition, Liquidity, and
Capital Resources in MD&A for details of our acquisitions in fiscal years 2010 and 2009.
Acquisitions are segregated in this presentation for one year from the acquisition date. |
For a more detailed discussion of the factors affecting the net sales comparison, see the
Seeds and Genomics Segment and the Agricultural Productivity Segment sections.
Gross profit decreased 17 percent in the three-month comparison. Gross profit as a
percent of net sales (gross profit percentage) for the total company decreased eight percentage
points to 54 percent in second quarter 2010 primarily driven by the decrease in ROUNDUP herbicides
average net selling prices. Gross profit percentage in the Seed and Genomics Segment decreased
three percentage points to 62 percent in second quarter 2010. This decline was primarily driven by
higher U.S. hedged commodity prices, manufacturing costs for corn and corn seed restructuring. See
the Seeds and Genomics Segment section of MD&A for further details. Gross profit percentage for
the Agricultural Productivity segment decreased 41 percentage points to 14 percent in second
quarter 2010. This decline was due to lower average selling prices for ROUNDUP and other
glyphosate-based herbicides. See the Agricultural Productivity Segment section of the MD&A for
further details regarding the Agricultural Productivity gross profit.
Operating expenses decreased 13 percent, or $128 million, in second quarter 2010 from the
prior-year comparable quarter. In the three-month comparison, selling, general and administrative
(SG&A) expenses decreased two percent primarily because of lower spending for administrative
functions and incentives as well as savings from restructuring actions. R&D expenses increased five
percent related to the increase in our expanded product pipeline. As a percent of net sales, SG&A
and R&D expenses remained constant at 13 percent and seven percent, respectively.
Interest expense increased $15 million in the three-month comparison as a result of increased
customer financing activity and programs during second quarter 2010 compared to the prior-year
second quarter.
Interest income decreased $4 million in the quarter-over-quarter comparison because of lower
average cash balances in the United States and lower interest rates in second quarter 2010.
Other expense net was expense of $2 million in second quarter 2010, compared with expense of $32
million in the prior-year quarter. The decrease occurred due to a decline in foreign currency
losses in the current year.
Income tax provision was $360 million in second quarter 2010, a decrease of $80
million over the prior-year quarter primarily as a result of the decrease in pretax income from
continuing operations. The effective tax rate of 29 percent in second quarter 2010 was the same as
the prior-year quarter. Second quarter 2010 included several discrete tax adjustments
resulting in a tax benefit of $16 million. The majority of this benefit resulted from the
resolution of domestic tax matters, the expiration of statutes in several ex-US jurisdictions, and
favorable adjustments from the preparation of tax returns in several jurisdictions. Second quarter
2009 included several discrete tax adjustments resulting in a tax benefit of $51 million. The
majority of this benefit was the result of the resolution of several domestic and ex-US tax audits.
Without the discrete items, our effective tax rate for second quarter 2010 would have been lower
than the 2009 rate, primarily driven by a shift in our projected earnings mix to lower tax rate
jurisdictions.
35
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
First Half of Fiscal Year 2010
The following explanations discuss the significant components of our results of operations
that affected the six-month comparison of our first half of fiscal years 2010 and 2009 income from
continuing operations:
Net sales decreased 16 percent in first half 2010 from the same period a year ago. Our
Seeds and Genomics segment net sales increased three percent, and our Agricultural Productivity
segment net sales declined 49 percent. The following table presents the percentage changes in first
half 2010 worldwide net sales by segment compared with net sales in the prior-year first half,
including the effect volume, price, currency and acquisitions had on these percentage changes:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
First Half 2010 Percentage Change in Net Sales vs. First Half 2009 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of |
|
|
|
|
|
|
Volume |
|
|
Price |
|
|
Currency |
|
|
Subtotal |
|
|
Acquisitions(1) |
|
|
Net Change |
|
|
|
|
Seeds and Genomics Segment |
|
|
(1) |
% |
|
|
2 |
% |
|
|
2 |
% |
|
|
3 |
% |
|
|
|
|
|
|
3 |
% |
Agricultural Productivity
Segment |
|
|
(3) |
% |
|
|
(46) |
% |
|
|
|
|
|
|
(49) |
% |
|
|
|
|
|
|
(49) |
% |
Total Monsanto Company |
|
|
(2) |
% |
|
|
(16) |
% |
|
|
2 |
% |
|
|
(16) |
% |
|
|
|
|
|
|
(16) |
% |
|
|
|
|
(1) |
|
See Note 3 Business Combinations and Financial Condition, Liquidity, and
Capital Resources in MD&A for details of our acquisitions in fiscal years 2010 and 2009.
Acquisitions are segregated in this presentation for one year from the acquisition date. |
For a more detailed discussion of the factors affecting the net sales comparison, see the
Seeds and Genomics Segment and the Agricultural Productivity Segment sections.
Gross profit decreased 30 percent in the six-month comparison. Gross profit percentage for the
total company decreased ten percentage points to 51 percent in first half 2010 driven by decreases
in average net selling prices of ROUNDUP herbicides. Gross profit percentage in the Seed and
Genomics segment decreased three percentage points to 61 percent in first half 2010. This decline
was primarily because of higher U.S. hedged commodity prices, manufacturing costs for corn and corn
seed restructuring as well as a channel shift of more seed and trait sales as opposed to primarily
trait sales during first half of 2010. See the Seeds and Genomics Segment section of MD&A for
further details. Gross profit percentage for the Agricultural Productivity segment decreased
38 percentage points to 18 percent in the first six months of 2010 because of lower average selling
prices for ROUNDUP and other glyphosate-based herbicides. See the Agricultural Productivity
Segment section of the MD&A for the further information regarding the Agricultural Productivity
gross profit.
Operating expenses decreased 9 percent, or $153 million, in first half 2010 from the prior-year
comparable half. In the six-month comparison, SG&A expenses decreased six percent primarily because
of lower spending for marketing, administrative functions and incentives and savings from
restructuring actions, and R&D expenses increased six percent related to the increase in our
expanded product pipeline. As a percent of net sales, SG&A expenses increased two percentage points
to 18 percent, and R&D expenses increased two percentage points to 10 percent in the six-month
comparison.
Interest expense increased $31 million in the six-month comparison because of the increased
customer financing activity and programs during the first half of 2010 compared to the first half
of 2009.
Interest income decreased $18 million in the six-month comparison because of less interest earned
on lower average cash balances in the United States and Brazil in first half 2010.
Other (income) expense net was a gain of $10 million in the first half of 2010, compared with a
loss of $58 million in the prior-year first half. The change occurred due to the gain recorded on
the Seminium acquisition as well as a decline in foreign currency losses in the first six months of
2010.
Income tax provision was $330 million in first half 2010, a decrease of $286 million from
the prior-year comparable period primarily as a result of the decrease in pretax income from
continuing operations. The effective tax rate increased to 28 percent from 27 percent in the prior
period. First half 2010 included several discrete tax adjustments resulting in a tax benefit of $32
million. The majority of this benefit resulted from the expiration of statutes in several
jurisdictions and the resolution of domestic and ex-U.S. tax matters. In addition, favorable
adjustments were recorded as a result of the preparation of tax
36
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
returns in several jurisdictions.
First half 2009 included several discrete tax adjustments resulting in a tax benefit of $95
million. The majority of this benefit was the result of the resolution of several domestic and
ex-US tax audits and the retroactive extension of the R&D credit that was enacted on Oct. 3, 2008,
as part of the Emergency Economic Stabilization Act of 2008. Without the discrete items, our
effective tax rate for first half 2010 would have been lower than the 2009 rate, primarily driven
by a shift in our projected earnings mix to lower tax rate jurisdictions.
SEEDS AND GENOMICS SEGMENT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
Six Months Ended Feb. 28, |
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
Change |
|
|
2010 |
|
|
2009 |
|
|
Change |
|
|
|
|
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corn seed and traits |
|
$ |
2,247 |
|
|
$ |
2,078 |
|
|
|
8 |
% |
|
$ |
2,816 |
|
|
$ |
2,706 |
|
|
|
4 |
% |
Soybean seed and traits |
|
|
633 |
|
|
|
615 |
|
|
|
3 |
% |
|
|
834 |
|
|
|
827 |
|
|
|
1 |
% |
Cotton seed and traits |
|
|
34 |
|
|
|
33 |
|
|
|
3 |
% |
|
|
93 |
|
|
|
80 |
|
|
|
16 |
% |
Vegetable seeds |
|
|
223 |
|
|
|
209 |
|
|
|
7 |
% |
|
|
396 |
|
|
|
366 |
|
|
|
8 |
% |
All other crops seeds and traits |
|
|
111 |
|
|
|
107 |
|
|
|
4 |
% |
|
|
140 |
|
|
|
162 |
|
|
|
(14) |
% |
|
|
|
Total Net Sales |
|
$ |
3,248 |
|
|
$ |
3,042 |
|
|
|
7 |
% |
|
$ |
4,279 |
|
|
$ |
4,141 |
|
|
|
3 |
% |
|
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corn seed and traits |
|
$ |
1,420 |
|
|
$ |
1,412 |
|
|
|
1 |
% |
|
$ |
1,724 |
|
|
$ |
1,815 |
|
|
|
(5) |
% |
Soybean seed and traits |
|
|
386 |
|
|
|
373 |
|
|
|
3 |
% |
|
|
525 |
|
|
|
518 |
|
|
|
1 |
% |
Cotton seed and traits |
|
|
15 |
|
|
|
21 |
|
|
|
(29) |
% |
|
|
48 |
|
|
|
47 |
|
|
|
2 |
% |
Vegetable seeds |
|
|
138 |
|
|
|
115 |
|
|
|
20 |
% |
|
|
250 |
|
|
|
195 |
|
|
|
28 |
% |
All other crops seeds and traits |
|
|
53 |
|
|
|
56 |
|
|
|
(5) |
% |
|
|
62 |
|
|
|
80 |
|
|
|
(23) |
% |
|
|
|
Total Gross Profit |
|
$ |
2,012 |
|
|
$ |
1,977 |
|
|
|
2 |
% |
|
$ |
2,609 |
|
|
$ |
2,655 |
|
|
|
(2) |
% |
|
|
|
EBIT(1) |
|
$ |
1,362 |
|
|
$ |
1,212 |
|
|
|
12 |
% |
|
$ |
1,305 |
|
|
$ |
1,277 |
|
|
|
2 |
% |
|
|
|
|
|
|
(1) |
|
EBIT is defined as earnings (loss) before interest and taxes. Interest and taxes
are recorded on a total company basis. We do not record these items at the segment level. See
Note 21 Segment Information and the Overview Non-GAAP Financial Measures section of MD&A
for further details. |
Seeds and Genomics Financial Performance Second Quarter Fiscal Year 2010
Net sales of corn seed and traits increased eight percent, or $169 million, in the three-month
comparison, primarily because of higher sales in Brazil and the United States due to an increase in
the average net selling price.
The net sales increases discussed throughout this section resulted in $35 million higher gross
profit in second quarter 2010. Gross profit as a percent of sales for this segment decreased three
percentage points in the quarter-over-quarter comparison to 62 percent. This decline was primarily
driven by higher U.S. hedged commodity prices and manufacturing costs for corn. In addition, we
recorded inventory impairments of $54 million related to discontinued corn seed products in the
United States in the three months ended Feb. 28, 2010, as part of our 2009 Restructuring Plan. See
Note 5 Restructuring for further information.
EBIT for the Seeds and Genomics segment increased $150 million to $1,362 million in second quarter
2010.
Seeds and Genomics Financial Performance First Half of Fiscal Year 2010
Net sales of corn seed and traits increased 4 percent, or $110 million, in the six-month
comparison, primarily because of higher sales in the United States due to an increase in the
average net selling price. Offsetting this increase, net sales of corn seed and traits decreased in
Mexico primarily due to earlier demand in the selling season.
All other crops seeds and traits net sales decreased 14 percent, or $22 million, in the first half
of 2010 primarily because of the divestiture of our global sunflower assets in August 2009.
Gross profit decreased $46 million in the first half of 2010. Gross profit as a percent of sales
for this segment decreased 3 percentage points in the period-over-period comparison to 61 percent.
This decline was primarily because of higher U.S.
37
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
hedged commodity prices and manufacturing costs
for corn as well as a channel shift to more seed and trait sales as opposed to primarily trait
sales during the first half of 2010. In addition, we recorded inventory impairments of $54 million
related to
discontinued corn seed products in the United States in the six months ended Feb. 28, 2010, as part
of our 2009 Restructuring Plan. See Note 5 Restructuring for further information. Partially
offsetting this decline, gross profit as a percent of sales increased ten percentage points for
vegetables in the six-month comparison due to improved product availability, mix, parity and the
successful integration of the De Ruiter acquisition.
EBIT for the Seeds and Genomics segment increased $28 million to $1,305 million in the first half
of 2010.
AGRICULTURAL PRODUCTIVITY SEGMENT
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, |
|
Six Months Ended Feb. 28, |
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
Change |
|
|
2010 |
|
|
2009 |
|
|
Change |
|
|
|
|
Net Sales |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ROUNDUP and other glyphosate-based herbicides |
|
$ |
465 |
|
|
$ |
776 |
|
|
|
(40 |
)% |
|
$ |
974 |
|
|
$ |
2,135 |
|
|
|
(54 |
)% |
All other agricultural productivity products |
|
|
177 |
|
|
|
217 |
|
|
|
(18 |
)% |
|
|
334 |
|
|
|
408 |
|
|
|
(18 |
)% |
|
|
|
Total Net Sales |
|
$ |
642 |
|
|
$ |
993 |
|
|
|
(35 |
)% |
|
$ |
1,308 |
|
|
$ |
2,543 |
|
|
|
(49 |
)% |
|
|
|
Gross Profit |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ROUNDUP and other glyphosate-based herbicides |
|
$ |
(1 |
) |
|
$ |
437 |
|
|
|
(100 |
)% |
|
$ |
86 |
|
|
$ |
1,241 |
|
|
|
(93 |
)% |
All other agricultural productivity products |
|
|
88 |
|
|
|
107 |
|
|
|
(18 |
)% |
|
|
143 |
|
|
|
175 |
|
|
|
(18 |
)% |
|
|
|
Total Gross Profit |
|
$ |
87 |
|
|
$ |
544 |
|
|
|
(84 |
)% |
|
$ |
229 |
|
|
$ |
1,416 |
|
|
|
(84 |
)% |
|
|
|
EBIT(1) |
|
$ |
(87 |
) |
|
$ |
326 |
|
|
|
(127 |
)% |
|
$ |
(53 |
) |
|
$ |
999 |
|
|
|
(105 |
)% |
|
|
|
|
|
|
(1) |
|
EBIT is defined as earnings (loss) before interest and taxes. Interest and taxes are
recorded on a total company basis. We do not record these items at the segment level. See Note
21 Segment Information and the Overview Non-GAAP Financial Measures section of MD&A for
further details. |
Agricultural Productivity Financial Performance Second Quarter Fiscal Year 2010
Net sales of ROUNDUP and other glyphosate-based herbicides decreased 40 percent, or $311 million,
in the three-month comparison, primarily in the United States and Europe. The average net selling
price decreased in all regions in second quarter 2010 compared to second quarter 2009 due to a
previously announced price decrease on our products. Partially offsetting this decline is an
increase in sales volumes of ROUNDUP and other glyphosate-based herbicides of 27 percent in second
quarter 2010 from second quarter 2009, primarily in Brazil, Argentina, Asia and the United States.
The net sales decreases discussed throughout this section resulted in $457 million lower gross
profit in second quarter 2010. Gross profit as a percent of sales for the Agricultural Productivity
segment decreased 41 percentage points to 14 percent in second quarter 2010 because of lower
average selling prices for ROUNDUP and other glyphosate-based herbicides. EBIT for the Agricultural
Productivity segment decreased $413 million to a loss of $87 million in second quarter 2010 due to
lower net selling prices partially offset by savings in SG&A.
Agricultural Productivity Financial Performance First Half of Fiscal Year 2010
Net sales of ROUNDUP and other glyphosate-based herbicides decreased 54 percent, or $1,161 million,
in the six-month comparison, especially in Brazil, the United States and Europe. The average net
selling price decreased in all regions in the first six months of 2010 compared to the first six
months of 2009 due to a previously announced price decrease on our products. Offsetting this
decline is a slight increase in sales volumes of ROUNDUP and other glyphosate-based herbicides of
three percent in the period-over-period comparison, primarily in Argentina, Asia and the United
States.
The net sales decreases discussed throughout this section resulted in $1,187 million lower gross
profit in the first half of 2010. Gross profit as a percent of sales for the Agricultural
Productivity segment decreased 38 percentage points to 18 percent in the period-over-period
comparison because of lower average selling prices for ROUNDUP and other glyphosate-based
herbicides. EBIT for the Agricultural Productivity segment decreased $1,052 million to a loss of
$53 million in the first half of 2010 due to lower net selling prices partially offset by savings
in SG&A.
38
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
Restructuring charges were recorded in the Statements of Consolidated Operations as follows:
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
|
Six Months Ended |
|
(Dollars in millions) |
|
Feb. 28, 2010 |
|
|
Feb. 28, 2010 |
|
|
|
|
|
Costs of Goods Sold(1) |
|
$ |
(54 |
) |
|
$ |
(54 |
) |
Restructuring Charges, Net(1)(2) |
|
|
(30 |
) |
|
|
(44 |
) |
|
|
|
|
Loss from Continuing Operations Before Income Taxes |
|
|
(84 |
) |
|
|
(98 |
) |
Income Tax Benefit |
|
|
30 |
|
|
|
31 |
|
|
|
|
|
Net Loss |
|
$ |
(54 |
) |
|
$ |
(67 |
) |
|
|
|
|
|
|
|
(1) |
|
For the three months and six months ended Feb. 28, 2010, the $54 million of
restructuring charges recorded in cost of goods sold related to the Seeds and Genomics
segment. For the three months ended Feb. 28, 2010, the $30 million of restructuring charges
recorded in restructuring charges, net were split by segment as follows: $25 million in
Agricultural Productivity and $5 million in Seeds and Genomics. For the six months ended Feb.
28, 2010, the $44 million of restructuring charges were split by segment as follows: $36
million in Agricultural Productivity and $8 million in Seeds and Genomics. |
|
(2) |
|
The restructuring charges for the three and six months ended Feb. 28, 2010, include
reversals of $9 million and $11 million, respectively, related to the 2009 Restructuring Plan. |
On June 23, 2009, our Board of Directors approved a restructuring plan (2009 Restructuring
Plan) to take future actions to reduce costs in light of the changing market supply environment for
glyphosate. We created a separate division for our ROUNDUP and other herbicides business, which is
expected to better align spending and working capital needs. This action is designed to enable
Monsanto to stabilize the ROUNDUP business and allow it to deliver optimal gross profit and a
sustainable level of operating cash in the coming years. We also announced that we will take steps
to better align the resources of our global seeds and traits business. These actions include
certain product and brand rationalization within our Vegetables and our U.S. corn businesses. On
Sept. 9, 2009, we committed to take additional actions related to the previously announced
restructuring plan. The plan is expected to be completed by the end of fiscal year 2010.
The total restructuring costs are expected to be in the range of $550 million to $600 million and
will be completed by the end of fiscal year 2010. The charges are expected to be comprised of
approximately $225 million to $250 million in severance and related benefits, $200 million to $225
million of costs related to site closures and product rationalization and $125 million of contract
termination costs. Payments related to the 2009 Restructuring Plan will be generated from cash from
operations.
39
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
The following table displays the pretax charges of $84 million and $98 million incurred by segment
under the 2009 Restructuring Plan for the three and six months ended Feb. 28, 2010, respectively,
as well as the cumulative pretax charges of $504 million under the 2009 Restructuring Plan.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended Feb. 28, 2010 |
|
Six Months Ended Feb. 28, 2010 |
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
(Dollars in millions) |
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
|
|
Work Force Reductions |
|
$ |
3 |
|
|
$ |
1 |
|
|
$ |
4 |
|
|
$ |
4 |
|
|
$ |
11 |
|
|
$ |
15 |
|
Facility Closures / Exit Costs |
|
|
2 |
|
|
|
24 |
|
|
|
26 |
|
|
|
3 |
|
|
|
25 |
|
|
|
28 |
|
Asset Impairments |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1 |
|
|
|
|
|
|
|
1 |
|
Inventory |
|
|
54 |
|
|
|
|
|
|
|
54 |
|
|
|
54 |
|
|
|
|
|
|
|
54 |
|
|
|
|
Total Restructuring Charges, Net |
|
$ |
59 |
|
|
$ |
25 |
|
|
$ |
84 |
|
|
$ |
62 |
|
|
$ |
36 |
|
|
$ |
98 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cumulative Amount through Feb. 28, 2010 |
|
|
Seeds and |
|
|
Agricultural |
|
|
|
|
(Dollars in millions) |
|
Genomics |
|
|
Productivity |
|
|
Total |
|
|
Work Force Reductions |
|
$ |
179 |
|
|
$ |
74 |
|
|
$ |
253 |
|
Facility Closures / Exit Costs |
|
|
6 |
|
|
|
72 |
|
|
|
78 |
|
Asset Impairments |
|
|
|
|
|
|
|
|
|
|
|
|
Property, plant and
equipment |
|
|
32 |
|
|
|
4 |
|
|
|
36 |
|
Inventory |
|
|
78 |
|
|
|
|
|
|
|
78 |
|
Other intangible assets |
|
|
59 |
|
|
|
|
|
|
|
59 |
|
|
Total Restructuring Charges, Net |
|
$ |
354 |
|
|
$ |
150 |
|
|
$ |
504 |
|
|
Our written human resource policies are indicative of an ongoing benefit arrangement with
respect to severance packages. Benefits paid pursuant to an ongoing benefit arrangement are
specifically excluded from the Exit or Disposal Cost Obligations topic of the ASC, therefore
severance charges incurred in connection with the 2009 Restructuring Plan are accounted for when
probable and estimable as required under the Compensation Nonretirement Postemployment Benefits
topic of the ASC.
In the six months ended Feb. 28, 2010, pretax restructuring charges of $98 million were recorded.
The $15 million in work force reductions relate primarily to Europe. The facility closures/exit
costs of $28 million relate primarily to the finalization of the termination of a chemical supply
contract in the United States. In asset impairments, inventory impairments of $54 million recorded
in cost of goods sold related to discontinued corn seed products in the United States.
The actions related to this restructuring plan are expected to produce annual cost savings of $220
million to $250 million, primarily in cost of goods sold and SG&A. Approximately one-third of these
savings are expected to be recognized in fiscal year 2010, with the full benefit realized in 2011.
40
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
FINANCIAL CONDITION, LIQUIDITY, AND CAPITAL RESOURCES
|
|
|
|
|
|
|
|
|
|
|
|
|
Working Capital and Financial Condition |
|
|
As of Feb. 28, |
|
As of Aug. 31, |
(Dollars in millions, except current ratio) |
|
2010 |
|
|
2009 |
|
|
2009 |
|
|
|
Cash and Cash Equivalents |
|
$ |
1,607 |
|
|
$ |
2,004 |
|
|
$ |
1,956 |
|
Trade Receivables, Net |
|
|
2,093 |
|
|
|
2,171 |
|
|
|
1,556 |
|
Inventory, Net |
|
|
3,199 |
|
|
|
3,112 |
|
|
|
2,934 |
|
Other Current Assets(1) |
|
|
1,346 |
|
|
|
1,183 |
|
|
|
1,437 |
|
|
|
|
|
Total Current Assets |
|
$ |
8,245 |
|
|
$ |
8,470 |
|
|
$ |
7,883 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Short-Term Debt |
|
$ |
114 |
|
|
$ |
110 |
|
|
$ |
79 |
|
Accounts Payable |
|
|
673 |
|
|
|
761 |
|
|
|
676 |
|
Accrued Liabilities(2) |
|
|
2,892 |
|
|
|
3,780 |
|
|
|
3,001 |
|
|
|
|
|
Total Current Liabilities |
|
$ |
3,679 |
|
|
$ |
4,651 |
|
|
$ |
3,756 |
|
|
|
|
|
Working Capital(3) |
|
$ |
4,566 |
|
|
$ |
3,819 |
|
|
$ |
4,127 |
|
Current Ratio(3) |
|
|
2.24:1 |
|
|
|
1.82:1 |
|
|
|
2.10:1 |
|
|
|
|
|
|
|
|
(1) |
|
Includes miscellaneous receivables, deferred tax assets and other current assets. |
|
(2) |
|
Includes income taxes payable, accrued compensation and benefits, accrued marketing
programs, deferred revenues, grower production accruals, dividends payable, customer payable,
restructuring reserves and miscellaneous short-term accruals. |
|
(3) |
|
Working capital is total current assets less total current liabilities; current
ratio represents total current assets divided by total current liabilities. |
Feb. 28, 2010, compared with Aug. 31, 2009: Working capital increased $439 million between
Aug. 31, 2009, and Feb. 28, 2010, because of the following factors:
|
|
|
Trade receivables increased $537 million due to normal ongoing sales activity. |
|
|
|
|
Inventory increased $265 million between the respective periods primarily because of the
seasonality of our U.S. corn and soybean seed business in which the fall harvest of seed
products occurs in the first half of the fiscal year resulting in a higher inventory
balance as of Feb. 28, 2010. Partially offsetting this increase was an inventory impairment
of $54 million related to discontinued corn seed products in the United States which was
part of our 2009 Restructuring Plan. |
|
|
|
|
Accrued marketing programs decreased $267 million due to a decrease in current year
Agricultural Productivity segment sales. |
|
|
|
|
Customer payable decreased $307 million during the first half of 2010 due to payments to
our customers for prior season overpayments. |
These increases to working capital between Aug. 31, 2009, and Feb. 28, 2010, were significantly
offset by the following factors:
|
|
|
Cash and cash equivalents decreased $349 million between the respective periods. See the
Cash Flow section in this section of MD&A for further details of this decrease. |
|
|
|
|
Income taxes payable increased $187 million primarily due to the seasonality of U.S.
results coupled with the timing of U.S. income tax payments. |
|
|
|
|
Deferred revenue increased $382 million related to customer prepayments. |
41
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
Feb. 28, 2010, compared with Feb. 28, 2009: Working capital increased $747 million between Feb. 28,
2010, and Feb. 28, 2009. The following factors increased working capital as of Feb. 28, 2010,
compared with Feb. 28, 2009:
|
|
|
Inventory increased $87 million primarily because of higher corn inventory carryover and
increased costs. Partially offsetting this increase was an inventory impairment of $54
million related to discontinued corn seed products in the United States which was part of
our 2009 Restructuring Plan. |
|
|
|
|
Accrued liabilities decreased $888 million. Income taxes payable decreased $274 million
primarily due to a decrease in U.S. pretax income. Accrued marketing programs related to
current year sales decreased $152 million due to the decline in sales and timing of
payments. Further, a decrease of $421 million in deferred revenue, and grower production
accruals decreased $100 million as less seed volumes were produced this period. |
These working capital increases were partially offset by the following factors:
|
|
|
Cash and cash equivalents decreased $397 million between the respective periods. See the
Cash Flow section in this section of MD&A and the Cash Flow section of Monsantos
Report on Form 10-K for the fiscal year ended Aug. 31, 2009, for further details of this
decrease. |
|
|
|
|
Trade receivables decreased $78 million due to a decrease in current year sales compared
to prior year. |
|
|
|
|
Restructuring reserves increased $197 million due to the 2009 Restructuring Plan. |
Customer Financing Programs: We previously established a revolving financing program of up to $250
million, which allowed certain U.S. customers to finance their product purchases, royalties and
licensing fee obligations. We received $130 million in first six months of 2009 from the proceeds
of loans made to our customers through this financing program. These proceeds are included in the
net cash provided by operating activities in the Statements of Consolidated Cash Flows. We
originated these customer loans on behalf of the third-party specialty lender, a special-purpose
entity (SPE) that we consolidated, using our credit and other underwriting guidelines approved by
the lender. We serviced the loans and provided a first-loss guarantee of up to $130 million.
Following origination, the lender transferred the loans to multi-seller commercial paper conduits
through a nonconsolidated qualifying special-purpose entity (QSPE). We had no ownership interest in
the lender, in the QSPE, or in the loans. We accounted for this transaction as a sale, in
accordance with the Transfers and Servicing topic of the ASC. There were no loan balances
outstanding as of Feb. 28, 2010, and Aug. 31, 2009. The program was terminated in the third quarter
of fiscal year 2009.
During the second quarter 2010, we began participating in a revolving financing program in Brazil
that allows us to transfer up to 1 billion Brazilian reais (approximately $550 million) in customer
receivables to a QSPE. Third parties, primarily investment funds, hold an 88 percent senior
interest in the QSPE, and we hold the remaining 12 percent subordinate interest. Because QSPEs are
excluded from the scope of the current guidance within the Consolidation topic of the ASC, and we
do not have the unilateral right to liquidate the QSPE, the consolidation guidance does not have an
effect on our accounting for this customer financing program.
Our investment in the QSPE was $4 million as of Feb. 28, 2010, and is included in other assets in
the Condensed Statements of Consolidated Financial Position and is classified as a debt security.
Interest earned on our investment in the QSPE was less than $1 million for the three months ended
Feb. 28, 2010, and is included in interest income on the Statements of Consolidated Operations.
Under the financing program, our transfer of select customer receivables to the QSPE is accounted
for as a sale in accordance with the Transfers and Servicing topic of the ASC. We do not service
the receivable; however, under the QSPE a recourse provision requires us to cover the first 12
percent of credit losses within the program.
Proceeds from customer receivables sold through the financing program and derecognized from the
Condensed Statements of Consolidated Financial Position totaled $47 million in fiscal year 2010.
These proceeds are included in net cash provided by operating activities in the Statements of
Consolidated Cash Flows and are net of a loss on sale of receivables of $3 million for the six
months ended Feb. 28, 2010. The remaining receivable balance in the QSPE outstanding as of Feb. 28,
2010, was $43
42
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
million. As of Feb. 28, 2010, there were no receivables sold through this financing
program that were delinquent. However,
based on our historical collection experience with these customers and a current assessment of
credit exposure, we recorded our recourse provision at $2 million as of Feb. 28, 2010. Adverse
changes in the actual loss rate would decrease our investment asset. The maximum potential amount
of future payments under the recourse provision was $6 million as of Feb. 28, 2010. If we are
called upon to make payments under the recourse provision, we would have the benefit under the
financing program of any amounts subsequently collected from the customer.
We also have agreements with lenders to establish programs to provide financing of up to 550
million Brazilian reais (approximately $300 million) for selected customers in Brazil. These
agreements qualify for sales treatment under the Transfers and Servicing topic of the ASC. Proceeds
from the transfer of the receivables are included in net cash provided by operating activities in
the Statements of Consolidated Cash Flows. We received $114 million and $91 million of proceeds
through these customer financing programs in the first six months of 2010 and 2009, respectively.
The amount of loans outstanding was $177 million and $160 million as of Feb. 28, 2010, and Aug. 31,
2009, respectively. In this program, we provide a full guarantee of the loans in the event of
customer default. The maximum potential amount of future payments under the guarantees was $177
million as of Feb. 28, 2010. The liability for the guarantee is recorded at an amount that
approximates fair value and is primarily based on our historical collection experience with
customers that participate in the program and a current assessment of credit exposure. Our
guarantee liability was $8 million and $6 million as of Feb. 28, 2010, and Aug. 31, 2009,
respectively. If performance is required under the guarantee, we may retain amounts that are
subsequently collected from customers.
We also have similar agreements with banks that provide financing to our customers in Brazil
through credit programs that are subsidized by the Brazilian government. In addition, there are
similar financing programs with financial institutions in the United States, Europe and Argentina.
Proceeds from the payment of receivables through the programs described above are included in net
cash provided by operating activities in the Statements of Consolidated Cash Flows. We received
$103 million and $51 million of proceeds through these customer financing programs in the first six
months of 2010 and 2009, respectively. The amount of loans outstanding was $52 million and $48
million as of Feb. 28, 2010, and Aug. 31, 2009, respectively. For most programs, we provide a full
guarantee of the loans in the event of customer default. The terms of guarantees are equivalent to
the terms of the bank loans. The maximum potential amount of future payments under the guarantees
was $52 million as of Feb. 28, 2010. The liability for the guarantee is recorded at an amount that
approximates fair value and is primarily based on our historical collection experience with
customers that participate in the program and a current assessment of credit exposure. Our
guarantee liability was $4 million and $5 million as of Feb. 28, 2010, and Aug. 31, 2009,
respectively. If performance is required under the guarantee, we may retain amounts that are
subsequently collected from customers.
In August 2009, we entered into an agreement in the United States to sell customer receivables up
to a maximum of $500 million and to service such accounts. The program will terminate in August
2012. These receivables qualify for sales treatment under the Transfers and Servicing topic of the
ASC and, accordingly, the proceeds are included in net cash provided by operating activities in the
Statements of Consolidated Cash Flows. The gross amount of receivables sold totaled $2 million for
the first six months of fiscal year 2010. The agreement includes recourse provisions and thus a
liability was established at the time of sale which approximates fair value based upon our
historical collection experience with such receivables and a current assessment of credit exposure.
The recourse liability recorded by us was $2 million as of Feb. 28, 2010, and Aug. 31, 2009. The
maximum potential amount of future payments under the recourse provisions of the agreement was $4
million as of Feb. 28, 2010. The outstanding balance of the receivables sold was $14 million and
$319 million as of Feb. 28, 2010, and Aug. 31, 2009, respectively. There were delinquent loans of
$14 million as of Feb. 28, 2010, and there were no delinquent accounts as of Aug. 31, 2009.
We sell accounts receivable in European regions both with and without recourse. These sales qualify
for sales treatment under the Transfers and Servicing topic of the ASC and, accordingly, the
proceeds are included in net cash provided by operating activities in the Statements of
Consolidated Cash Flows. The gross amounts of accounts receivable sold totaled $15 million and $1
million for the first six months of 2010 and 2009, respectively. The liability for the guarantees
for sales with recourse is recorded at an amount that approximates fair value and is based on our
historical collection experience for the customers associated with the sales of the accounts
receivable and a current assessment of credit exposure. Our guarantee liability was less than $1
million as of Feb. 28, 2010, and Aug. 31, 2009. The maximum potential amount of future payments
43
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
under the recourse provisions of the agreements was $5 million as of Feb. 28, 2010. The outstanding
balance of the receivables sold was $5 million and $57 million as of Feb. 28, 2010, and Aug. 31,
2009, respectively.
Cash Flow
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended Feb. 28, |
(Dollars in millions) |
|
2010 |
|
|
2009 |
|
|
Net Cash Provided by Operating Activities |
|
$ |
256 |
|
|
$ |
1,500 |
|
Net Cash Required by Investing Activities |
|
|
(345 |
) |
|
|
(359 |
) |
|
Free Cash Flow(1) |
|
|
(89 |
) |
|
|
1,141 |
|
|
Net Cash Required by Financing Activities |
|
|
(259 |
) |
|
|
(601 |
) |
Effect of Exchange Rate Changes on Cash and Cash Equivalents |
|
|
(1 |
) |
|
|
(149 |
) |
|
Net (Decrease) Increase in Cash and Cash Equivalents |
|
|
(349 |
) |
|
|
391 |
|
Cash and Cash Equivalents at Beginning of Period |
|
|
1,956 |
|
|
|
1,613 |
|
|
Cash and Cash Equivalents at End of Period |
|
$ |
1,607 |
|
|
$ |
2,004 |
|
|
|
|
|
(1) |
|
Free cash flow represents the total of net cash provided or required by operating
activities and provided or required by investing activities (see the Non-GAAP Financial
Measures section in MD&A for a further discussion). |
Cash provided by operating activities was $256 million in first half 2010 compared with $1,500
million in first half 2009. The decrease of $1,244 million was driven by the change in accounts
payable and other accrued liabilities of $725 million in the six-month comparison because of lower
commodity prices and reduced market funding. In addition, the decrease was also driven by the
decline in net income of $781 million in the six-month comparison from $1,651 million to $870
million. Further, the change in accounts receivable of $205 million provided less cash from lower
collections during the current year. In the prior-year first half, we incurred a non-cash acquired
in-process R&D pre-tax charge of $162 million. These decreases were partially offset by a change in
cash provided by inventory of $731 million which occurred primarily because of a decline in
inventory production.
Cash required by investing activities was $345 million in first half 2010 compared to $359 million
in first half 2009. In second quarter 2009, we received proceeds of $300 million related to the
sale of the Dairy business. Offsetting this increase in the prior year we acquired the sugarcane
business for $264 million, and there was no similar sized acquisition in the current year. Further,
our capital expenditures decreased $119 million in the six-month comparison due to less spending in
the first half of the current year.
The amount of cash required by financing activities was $259 million in the first six months of
2010 compared with $601 million in the first six months of 2009. The net change in short-term
financing was a source of cash of $119 million in first half 2010 compared with a use of cash of
$18 million in the prior-year first half primarily due to an increase in short-term borrowings to
support ex-U.S. operations during the current fiscal year. Further, treasury stock purchases
declined $150 million as we did not repurchase as many shares during the first six months of 2010
compared to the comparable prior-year period.
Capital Resources and Liquidity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of Feb. 28, |
|
As of Aug. 31, |
(Dollars in millions, except debt-to-capital ratio) |
|
2010 |
|
|
2009 |
|
|
2009 |
|
|
|
Short-Term Debt |
|
$ |
114 |
|
|
$ |
110 |
|
|
$ |
79 |
|
Long-Term Debt |
|
|
1,726 |
|
|
|
1,704 |
|
|
|
1,724 |
|
Total Shareowners Equity |
|
|
10,701 |
|
|
|
9,604 |
|
|
|
10,056 |
|
Debt-to-Capital Ratio |
|
|
15 |
% |
|
|
16 |
% |
|
|
15 |
% |
|
|
|
|
A major source of our liquidity is operating cash flows, which are derived from net income.
This cash-generating capability provides us with the financial flexibility we need to meet
operating, investing and financing needs. To the extent that cash provided by operating activities
is not sufficient to fund our cash needs, which generally occurs during the first and third
quarters of the fiscal year because of the seasonal nature of our business, short-term commercial
paper borrowings are used to finance these requirements. Although the commercial paper market has
not fully returned to historical levels, the market is
44
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
available to those companies with high
short-term credit ratings such as Monsantos. We accessed the commercial paper markets in 2010 for
short periods of time to finance working capital needs and our options have not been limited. We
had no commercial paper borrowings outstanding at Feb. 28, 2010.
Total debt outstanding increased $26 million between Feb. 28, 2009, and Feb. 28, 2010, primarily
because we have several short-term debt borrowings outstanding to support ex-U.S. operations.
We plan to
issue new fixed-rate debt on or before Aug. 15, 2012, to repay
$486 million of 73/8%
Senior Notes that are due on Aug. 15, 2012. In March 2009, we entered into forward starting
interest rate swaps with a total notional amount of $250 million. Our purpose was to hedge the
variability of the forecasted interest payments on this expected debt issuance that may result from
changes in the benchmark interest rate until the debt is issued.
We are currently evaluating the impact of the Patient Protection and Affordable Care Act signed by
President Obama on March 23, 2010, and the Heath Care and Education Act of 2010 signed on March 30,
2010 (collectively the Acts). We anticipate a tax charge of less than $10 million due to the
elimination of the tax benefit associated with the Medicare Part D subsidy included in the Acts. We
are still evaluating the other impacts from the Acts, but we do not expect them to have a material
impact on our consolidated financial statements.
Dividend: In January 2010, we declared a quarterly dividend of 26.5 cents payable on April 30,
2010, to shareowners of record as of April 9, 2010.
Capital Expenditures: We expect 2010 capital expenditures to be in the range of $750 million to
$850 million compared with $916 million in 2009. The primary driver of this decrease is lower
spending on projects to expand corn seed production facilities compared to prior year.
Purchase of Chesterfield Village Research Center: In November 2009, we entered into an agreement to
acquire Pfizers Chesterfield Village Research Center located in Chesterfield, MO. We are expected
to acquire the property in early April 2010 for $435 million which will be paid this year and over the next two
fiscal years.
Divestiture: In October 2008, we sold the Dairy business after receiving approval from the
appropriate regulatory agencies. During the six months ended Feb. 28, 2009, income from operations
of discontinued businesses included an $11 million pre-tax gain related to the sale.
2010 Acquisition: In October 2009, we acquired the remaining 51 percent equity interest in
Seminium, S.A. (Seminium), a leading Argentinean corn seed company. Acquisition costs were less
than $1 million for the six months ended Feb. 28, 2010, and classified as selling, general and
administrative expenses. The total fair value of Seminium was $36 million. This fair value includes
$20 million of cash paid (net of cash acquired) and $16 million for the fair value of Monsantos 49
percent equity interest in Seminium held prior to the acquisition.
2009 Acquisitions: In December 2008, we acquired 100 percent of the outstanding stock of Aly
Participacoes Ltda. (Aly), which operates the sugarcane breeding and technology companies,
CanaVialis S.A. and Alellyx S.A., both of which are based in Brazil, for 616 million Brazilian
reais or $264 million (net of cash acquired), inclusive of transaction costs of less than $1
million. We consummated the transaction with existing cash.
In July 2009, we acquired the assets of WestBred, LLC, a Montana-based company that specializes in
wheat germplasm, for $49 million (net of cash acquired), inclusive of transaction costs of $4
million. The acquisition will bolster the future growth of Monsantos seeds and traits platform.
2010 Contractual Obligations: There have been no significant changes to the contractual obligations
table as disclosed in our Annual Report on Form 10-K for the year ended Aug. 31, 2009, except as
discussed above.
45
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
Off-Balance Sheet Arrangement
Under our Separation Agreement with Pharmacia, we are required to indemnify Pharmacia for certain
matters, such as environmental remediation obligations and litigation. To the extent we are
currently managing any such matters, we evaluate them in the course of managing our own potential
liabilities and establish reserves as appropriate. However, additional matters may arise in the
future, and we may manage, settle or pay judgments or damages with respect to those matters in
order to mitigate contingent liability and protect Pharmacia and Monsanto. See Note 20
Commitments and Contingencies and Part II Item 1 Legal Proceedings for further information.
We have entered into various customer financing programs which are accounted for in accordance with
the Transfers and Servicing topic of the ASC. See Note 4 Customer Financing Programs for
further information.
OUTLOOK
We have achieved an industry-leading position in the areas in which we compete in both of our
business segments. However, the outlook for each part of our business is quite different. In the
Seeds and Genomics segment, our seeds and traits business is expected to expand. In the
Agricultural Productivity segment, our glyphosate business has grown through increases in our
average net selling prices in 2008 and 2009, however prices have declined in fiscal year 2010 and
are expected to remain lower than in 2008 and 2009. In 2009, our glyphosate volumes declined due to
share loss resulting from declining competitive prices and increasing competitive supply, as well
as from the effect of the drought in South America. Our selective chemistry business is expected to
decline. As a result, we are working to rebuild a competitive position in our chemistry business,
while we strive to expand our business in seeds and traits via our investment in new products.
We believe that our company is positioned to deliver value added products to growers enabling us to
grow our gross profit in the future. In the short term, we expect volatility in our ROUNDUP
business as it moves to a sustainable level of earnings. We expect to see strong cash flow as well
over the period, and we remain committed to returning value to shareowners through vehicles such as
investments that expand the business, dividends and share repurchases. We will remain focused on
cost and cash management for each segment, both to support the progress we have made in managing
our investment in working capital and to realize the full earnings potential of our businesses. We
plan to continue to seek additional external financing opportunities for our customers as a way to
manage receivables for each of our segments.
Economic activity in the United States and globally appears to be recovering from the slowdown seen
in fiscal year 2009. The instability in the global financial markets also appears to have eased,
and while credit availability is still restrained, markets are relatively stable. Outside of the
United States, our businesses will continue to face additional challenges related to the risks
inherent in operating in emerging markets. We expect to continue to monitor these developments and
the challenges and issues they place on our business. We believe we have taken appropriate measures
to manage our credit exposure, which has the potential to affect sales negatively in the near term.
In addition, volatility in foreign-currency exchange rates may negatively affect our profitability,
the book value of our assets outside the United States, and our shareowners equity.
Seeds and Genomics
Our capabilities in plant breeding and biotechnology research are generating a rich and balanced
product pipeline that we expect will drive long-term growth. We plan to continue to invest in the
areas of seeds, genomics and biotechnology and to invest in technology arrangements that have the
potential to increase the efficiency and effectiveness of our R&D efforts. We believe that our
seeds and traits businesses will have significant near-term growth opportunities through a
combination of improved breeding and continued growth of stacked and second-generation biotech
traits.
We expect advanced breeding techniques combined with improved production practices and capital
investments to continue to contribute to improved germplasm quality and yields for our seed
offerings, leading to increased global demand for both
46
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
our branded germplasm and our licensed
germplasm. Our vegetable portfolio will focus on 23 crops. We plan to continue to apply our
molecular breeding and marker capabilities to our vegetable seeds germplasm, which we expect will
lead to growth in that business. The integration of De Ruiter has improved our abilities to develop
and deliver new, innovative products to our broad customer base. The recent acquisition of Aly will
enable us to combine our areas of breeding expertise to enhance yields in sugarcane, a crop that is
vital to addressing growing global food and fuel demands. We also plan to continue making strategic
acquisitions in our seed businesses to grow our branded seed market share, expand our germplasm
library and strengthen our global breeding programs. We expect to see continued competition in
seeds and genomics in the near term.
We believe we will have a competitive advantage because of our global breeding capabilities and our
multiple channel sales approach in the United States for corn and soybean seeds.
Commercialization of second-generation traits and the stacking of multiple traits in corn and
cotton are expected to increase penetration in approved markets, particularly as we continue to
price our traits in line with the value growers have experienced. In 2010, we expect that
higher-value, stacked-trait products will represent a larger share of our total U.S. corn seed
sales than they did in 2009. Acquisitions may also present near-term opportunities to increase
penetration of our traits. We expect the competition in biotechnology to increase, as more
competitors launch traits in the United States and internationally. However, we believe we will
have a competitive advantage because we will be poised to deliver second- and third-generation
traits when our competitors are delivering their first-generation traits.
Approvals have been obtained in the United States and Canada, and key import countries of Japan,
Korea, Taiwan, Philippines, Mexico, Australia and New Zealand for our next generation corn product.
GENUITY SMARTSTAX, a product that contains five proteins that control important above ground (corn
borer, corn ear worm) and below ground (corn root worm) pests and provides tolerance to the
herbicides glyphosate and glufosinate, uses multiple modes of action for insect
control, the proven means to enhance performance, reduce structured refuge and maintain long-term
durability of corn trait technology. GENUITY SMARTSTAX uniquely features a combination of weed and
insect control traits that significantly reduces the risk of resistance for both above and below
ground pests. As a result, the U.S. EPA and the Canadian Food Inspection Agency allowed reduction
of the typical structured farm refuge from 20 percent to 5 percent for GENUITY SMARTSTAX in the
U.S. Corn Belt and Canada and from 50 percent to 20 percent for the U.S. Cotton Belt. GENUITY
SMARTSTAX corn was launched in the United States in 2010. A full regulatory submission was
completed for a 5 percent refuge-in-a-bag (RIB) seed blend to the U.S. EPA and Canadian Feed
Inspection Agency. GENUITY SMARTSTAX RIB would enable farmers in the Corn Belt to plant one corn
product across their entire field without the need to plant a separate refuge. Global cultivation
opportunities were expanded for corn and cotton with approval of BOLLGARD II Cotton in Brazil and
corn field trials in Mexico and Pakistan.
During 2007, we announced a long-term joint R&D and commercialization collaboration in plant
biotechnology with BASF that will focus on high-yielding crops and crops that are tolerant to
adverse conditions such as drought. We have completed all North American and key import country
regulatory submissions for the first biotech drought-tolerant corn product. Pending necessary
approvals, the product is on track for an introduction around 2012. Over the long-term life of the
collaboration, we and BASF will dedicate a joint budget of potentially $1.5 billion to fund a
dedicated pipeline of yield and stress tolerance traits for corn, soybeans, cotton and canola.
Our international traits businesses, in particular, will probably continue to face unpredictable
regulatory environments that may be highly politicized. We operate in volatile, and often
difficult, economic environments. Although we see growth potential in our India cotton business
with the ongoing conversion to higher planting rates with hybrids and BOLLGARD II, this business is
currently operating under state governmental pricing directives that we believe limit near-term
earnings growth in India.
In Brazil, notwithstanding continuing and varied legal challenges by private and governmental
parties, we expect to continue to operate our dual-track business model of certified seeds and our
point-of-delivery payment system (ROUNDUP READY soybeans) or our indemnification collection system
(BOLLARD cotton) to ensure that we capture value on all of our ROUNDUP READY soybeans and BOLLGARD
cotton crops grown there. Income is expected to grow as farmers choose to plant more of these
approved traits. Although Brazilian law clearly states that these products protected by pipeline
patents have the duration of the U.S. patent (2014 for ROUNDUP READY soybeans and 2011 for BOLLARD
cotton), legal rulings have not consistently achieved that outcome. Continued commercial approval
of new products such as the recently approved YIELDGARD VT PRO, YIELDGARD ROUNDUP READY 2 and
YIELDGARD Corn Borer will provide the opportunity
47
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
for a step change in contributions from seeds and
traits in Brazil. As noted above, YIELDGARD Corn Borer was approved recently, and was planted in the past
growing season. The agricultural economy in Brazil could be impacted by global commodity prices,
particularly for corn and soybeans. We continue to maintain our strict credit policy, expand our
grain-based collection system, and focus on cash collection and sales, as part of a continuous
effort to manage our Brazilian risk against such volatility.
Efforts to secure an orderly system in Argentina to support the introduction of new technology
products are underway. While it is unlikely that old technology ROUNDUP READY soybeans could be
subject to a system absent rulings of patent
infringement from ongoing court cases in Europe, we do not plan to commercialize new soybean or
cotton traits in Argentina until we can achieve more certainty that we will be compensated for
providing the technology. Three Spanish cases, which we have appealed, and a U.K. case have had
adverse early results regarding the old technology ROUNDUP READY soybeans. We settled the U.K.
case, and both we and the defendants have dismissed our appeals of that matter. The first case in
Holland has now been referred to the European Court of Justice (ECJ) for an interpretation of the
EU patent law for biotech products. The ECJ had a hearing on Dec. 15, 2009, and its Advocate
General delivered his opinion against patent enforcement on March 9, 2010. The Courts judgment is
expected later in 2010. Meanwhile, we are continuing to discuss alternative arrangements with
various Argentine stakeholders pertaining to new soybean and cotton trait products. However, we
have no certainty that any of these discussions will lead to an income producing outcome.
In March 2008, a judge of the French Supreme Administrative court (Conseil dEtat) rejected an
application for interim relief by French farmers, French grower associations and various companies,
including Monsanto, to overturn the French governments suspension of planting of YIELDGARD Corn
Borer pending review and completion under a new regulatory regime. The outcome means that there
will be no additional sales or planting of this product in France during the forthcoming growing
season. The European Food Safety Authority (EFSA) has issued an opinion that the French suspension
is not supported on a scientific basis. The case has now been referred to the European Court of
Justice (ECJ) and the ban remains in place. On April 17, 2009, Germany invoked the safeguard clause
and also banned the planting of YIELDGARD Corn Borer. We sought interim relief to overturn the ban
which the German administrative courts denied. As a result, there will be no sales or planting of
MON810 products in Germany this growing season. The court proceedings are postponed pending the
outcome of administrative proceedings. Other European Union Member States (e.g., Austria,
Luxembourg and Greece) have also invoked safeguard measures but we have focused our legal
challenges to those countries with significant corn plantings.
Agricultural Productivity
We believe our ROUNDUP herbicide gross profit peaked in 2008 and will decline in 2010 in light of
our previously announced U.S. price reduction and a global oversupply of low priced generic
material. However, we believe the business will continue to generate a strong source of cash and
gross profit. Prices of generic formulations of glyphosate herbicides increased during fiscal year
2008, but against a background of increased global supply and softening raw material prices,
generic prices are now at or near historical lows in many of our key markets. However, raw material
prices have started to increase again. We have experienced fluctuating demand in recent years, and
we recently successfully started-up new production capacity at our Luling, Louisiana, plant to meet
the anticipated future demand for ROUNDUP. We will continue to actively manage our inventory and
other costs.
We have submitted a mine plan to the U.S. Bureau of Land Management (BLM) regarding a new phosphate
ore mine near Soda Springs, Idaho, that we intend to use to meet existing and future production
demands for our ROUNDUP herbicides and licensed glyphosate. BLM is in the process of considering
the public comments on its draft Environmental Impact Statement (EIS) for the mine. We anticipate
receiving regulatory approvals for our new mine in calendar year 2010. However, we are aware that
certain environmental groups have initiated litigation against other phosphate producers to disrupt
and delay the permitting process.
Like most other selective herbicides, our selective acetochlor herbicide products face increasing
competitive pressures and a declining market, in part because of the rapid penetration of ROUNDUP
READY corn in the United States. We will continue to seek ways to optimize our selective herbicides
business, as we believe it is important to offer fully integrated crop-protection solutions,
particularly in ROUNDUP READY Corn 2. We anticipate a continued decline in this business in the
near term, but the gross profit from the ROUNDUP READY traits and from the ROUNDUP herbicides used
on these acres is significantly higher than the gross profit from the lost selective herbicide
sales.
48
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
The lawn-and-garden business should continue benefiting from the ROUNDUP brand equity in the
marketplace and remain a strong cash generator for Monsanto. Driving demand to more profitable
products will allow us to offset higher production costs and increased commission expenses owed to
The Scotts Miracle-Gro Company.
Other Information
As discussed in Note 20 Commitments and Contingencies and Part II Item 1 Legal Proceedings,
Monsanto is involved in a number of lawsuits and claims relating to a variety of issues. Many of
these lawsuits relate to intellectual property disputes. We expect that such disputes will continue
to occur as the agricultural biotechnology industry evolves.
Third parties, including non-governmental organizations, have challenged the validity or
enforceability of patents issued to the company regarding our biotechnology products. For
additional information related to the outlook for Monsanto, see Caution Regarding Forward-Looking
Statements at the beginning of this Report on Form 10-Q, Part II Item 1A Risk Factors below
and Part I Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2009.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
In preparing our financial statements, we must select and apply various accounting policies. Our
most significant policies are described in Part II Item 8 Note 2 Significant Accounting
Policies to the consolidated financial statements contained in our Report on Form 10-K for the
fiscal year ended Aug. 31, 2009. In order to apply our accounting policies, we often need to make
estimates based on judgments about future events. In making such estimates, we rely on historical
experience, market and other conditions, and on assumptions that we believe to be reasonable.
However, by its nature the estimation process is uncertain, given that estimates depend on events
over which we may not have control. If market and other conditions change from those that we
anticipate, our financial condition, results of operations, or liquidity may be affected
materially. In addition, if our assumptions change, we may need to revise our estimates or take
other corrective actions, either of which may have a material effect on our financial condition,
results of operations, or liquidity.
The estimates that have a higher degree of inherent uncertainty and require our most significant
judgments are outlined in Managements Discussion and Analysis of Financial Condition and Results
of Operations contained in our Report on Form 10-K for fiscal year ended Aug. 31, 2009. Had we used
estimates different from any of those contained in such Report on Form 10-K, our financial
condition, profitability, or liquidity for the current period could have been materially different
from those presented in this Form 10-Q.
49
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
NEW ACCOUNTING STANDARDS
In January 2010, the FASB issued an amendment to the Fair Value Measurements and Disclosures topic
of the ASC. This amendment requires disclosures about transfers into and out of Levels 1 and 2 and
separate disclosures about purchases, sales, issuances, and settlements relating to Level 3
measurements. It also clarifies existing fair value disclosures about the level of disaggregation
and about inputs and valuation techniques used to measure fair value. This amendment is effective
for periods beginning after Dec. 15, 2009, except for the requirement to provide the Level 3
activity of purchases, sales, issuances, and settlements, which will be effective for fiscal years
beginning after Dec. 15, 2010. Accordingly, we will adopt this amendment in third quarter 2010,
except for the additional Level 3 requirements which will be adopted in fiscal year 2011. We are
currently evaluating the disclosure impact of adopting this standard on the consolidated financial
statements.
In June 2009, the FASB issued its ASC Topic 105, Generally Accepted Accounting Principles, which
became the single source of authoritative GAAP (other than rules and interpretive releases of the
U.S. Securities and Exchange Commission). The ASC is topically based with topics organized by ASC
number and updated with Accounting Standards Updates (ASUs). ASUs will replace accounting guidance
that historically was issued as FASB Statements of Financial Accounting Standards (SFAS), FASB
Interpretations (FIN), FASB Staff Positions (FSP), Emerging Issues Task Force (EITF) Issues or
other types of accounting standards. The ASC became effective Nov. 30, 2009, for Monsanto and
disclosures within this Quarterly Report on Form 10-Q have been updated to reflect the change. The
ASC does not change GAAP and did not impact our consolidated financial statements.
In June 2009, the FASB issued a standard that requires an analysis to determine whether a variable
interest gives the entity a controlling financial interest in a variable interest entity. This
statement requires an ongoing reassessment and eliminates the quantitative approach previously
required for determining whether an entity is the primary beneficiary. This standard is effective
for fiscal years beginning after Nov. 15, 2009. Accordingly, we will adopt this standard in fiscal
year 2011. We are currently evaluating the impact of adoption on the consolidated financial
statements.
In June 2009, the FASB issued a standard that removes the concept of a qualifying special-purpose
entity (QSPE) from GAAP and removes the exception from applying consolidation principles to a QSPE.
This standard also clarifies the requirements for isolation and limitations on portions of
financial assets that are eligible for sale accounting. This standard is effective for fiscal years
beginning after Nov. 15, 2009. Accordingly, we will adopt this standard in fiscal year 2011. We are
currently evaluating the impact of adoption on our QSPE, other financing programs and on the
consolidated financial statements.
In April 2009, the FASB issued a standard that extends the previous disclosure requirements about
fair value of financial instruments to interim financial statements of publicly traded companies.
This standard requires that disclosures provide quantitative and qualitative information on fair
value estimates for all financial instruments not measured on the balance sheet at fair value, when
practicable, with the exception of certain financial instruments. This standard is effective
prospectively for interim reporting periods ending after June 15, 2009. Accordingly, we adopted
this standard in first quarter fiscal year 2010. See Note 12 Debt and Other Credit Arrangements,
Note 13 Fair Value Measurements and Note 14 Financial Instruments for the disclosures
required by this standard.
In December 2008, the FASB issued a standard that provides additional guidance regarding
disclosures about plan assets of defined benefit pension or other postretirement plans. This
standard is effective for financial statements issued for fiscal years ending after Dec. 15, 2009.
Accordingly, we will include the disclosure requirements of this standard in the Report on Form
10-K for the fiscal year ended Aug. 31, 2010. We are currently evaluating the disclosure impact of
adopting this standard on the consolidated financial statements.
In February 2008, the FASB issued a standard that delayed the effective date of the new guidance
regarding fair value measurement and disclosure for nonfinancial assets and liabilities to fiscal
years beginning after Nov. 15, 2008. Accordingly, we adopted the additional requirements of the
Fair Value Measurements and Disclosures topic of the ASC that were deferred by this standard in
first quarter fiscal year 2010. The adoption of this standard did not have an impact on our
consolidated
50
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
financial statements. See Note 12 Debt and Other Credit Arrangements and Note 13
Fair Value Measurements for additional discussion regarding fair value measurements.
In December 2007, the FASB issued a standard that requires an entity to clearly identify and
present its ownership interests in subsidiaries held by parties other than the entity in the
consolidated financial statements within the equity section but separate from the entitys equity.
It also requires the amount of consolidated net income attributable to the parent and to the
noncontrolling interest be clearly identified and presented on the face of the Statements of
Consolidated Operations; changes in ownership interest be accounted for similarly, as equity
transactions; and when a subsidiary is deconsolidated, any retained noncontrolling equity
investment in the former subsidiary and the gain or loss on the deconsolidation of the subsidiary
be measured at fair value. This statement is effective for financial statements issued for fiscal
years beginning after Dec. 15, 2008. The provisions of the standard related to accounting for
changes in ownership are to be applied prospectively, except for the presentation and disclosure
requirements, which are to be applied retrospectively. We adopted this standard on Sept. 1, 2009,
and the presentation and disclosure requirements of this standard were applied retrospectively to
all periods presented. The adoption of this standard did not have a material impact on the
consolidated financial statements, other than the following changes in presentation of
noncontrolling interests:
|
|
|
Consolidated net income was recast to include net income attributable to both the
company and noncontrolling interests in the Statements of Consolidated Operations. |
|
|
|
|
Noncontrolling interests were reclassified from other liabilities to equity, separate
from the parents shareowners equity, in the Condensed Statements of Consolidated
Financial Position. |
|
|
|
|
The Statements of Consolidated Cash Flows now begin with net income (including
noncontrolling interests) instead of net income attributable to Monsanto Company, with net
income from noncontrolling interests (previously, minority interests) no longer a
reconciling item in arriving at net cash provided by operating activities, and the
Statements of Consolidated Cash Flows were recast to include dividend payments to
noncontrolling interests. |
|
|
|
|
Interim Condensed Statements of Consolidated Shareowners Equity and Comprehensive
Income have been added to fulfill the disclosure requirements. |
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
There are no material changes related to market risk from the disclosures in Monsantos Report on
Form 10-K for the fiscal year ended Aug. 31, 2009.
ITEM 4. CONTROLS AND PROCEDURES
We maintain a comprehensive set of disclosure controls and procedures (as defined in Rules
13a-15(e) and 15d-15(e) under the Exchange Act) designed to ensure that information required to be
disclosed in our filings under the Exchange Act is recorded, processed, summarized and reported
accurately and within the time periods specified in the SECs rules and forms. As of Feb. 28, 2010
(the Evaluation Date), an evaluation was carried out under the supervision and with the
participation of our management, including our Chief Executive Officer and Chief Financial Officer,
of the effectiveness of the design and operation of our disclosure controls and procedures. Based
upon that evaluation, the Chief Executive Officer and Chief Financial Officer concluded that, as of
the Evaluation Date, the design and operation of these disclosure controls and procedures were
effective to provide reasonable assurance of the achievement of the objectives described above.
During the quarter that ended on the Evaluation Date, there was no change in internal control over
financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has
materially affected, or is reasonably likely to materially affect, our internal control over
financial reporting.
51
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
PART IIOTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
We are involved in various legal proceedings that arise in the ordinary course of our business, as
well as proceedings that we have considered to be material under SEC regulations. These include
proceedings to which we are party in our own name and proceedings to which our former parent
Pharmacia Corporation or its former subsidiary Solutia Inc. is a party but that we manage and for
which we are responsible. We believe we have meritorious legal arguments and will continue to
represent our interests vigorously in all of the proceedings that we are defending or prosecuting.
Information regarding certain material proceedings and the possible effects on our business of
proceedings we are defending is disclosed in Note 20 under the subheading Environmental and
Litigation Liabilities Litigation and is incorporated by reference herein. The following
discussion provides new and updated information regarding certain other proceedings for which we
are responsible. Other information with respect to legal proceedings appears in our Report on Form
10-K for the fiscal year ended Aug. 31, 2009.
Patent and Commercial Proceedings
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2009, and Monsantos
Report on Form 10-Q for the quarterly period ended Nov. 30, 2009, on Dec. 23, 2008, we entered into
a dispute resolution process with Pioneer Hi-Bred International, Inc. (Pioneer), a wholly owned
subsidiary of E. I. du Pont de Nemours and Company (DuPont), to address issues regarding the
unauthorized use of our proprietary technology. Pioneer has announced plans to combine or stack
their Optimum ® GAT ® trait in soybeans with our patented first generation ROUNDUP READY
technology, contrary to their previously disclosed plans to discontinue use of soybean varieties
containing our technology and pursue the Optimum® GAT® trait alone. We believe that Pioneer is not
authorized to make this genetic combination, and we are seeking to prevent non-consensual use of
our proprietary technology. On May 4, 2009, following unsuccessful discussions, Monsanto filed suit
against DuPont and Pioneer in Federal District Court in St. Louis asserting patent infringement and
breach of contract claims to prevent the unauthorized use of our ROUNDUP READY technology in corn
and soybeans. On June 16, 2009, the defendants filed an answer and counterclaim seeking injunctive
relief, damages and specific performance asserting a claim of license as well as the invalidity or
unenforceability of the patent asserted by Monsanto, and also claiming alleged anticompetitive
behavior relating to traits for corn and soybeans. The court, on Sept. 16, 2009, severed the
antitrust defense interposed by DuPont for a separate, subsequent trial following our case for
patent infringement and license breach. On Oct. 23, 2009, the Court heard our motion for judgment
on the pleadings to declare DuPont and Pioneer in breach of their corn and soybean licensing
agreements with us. On Jan. 15, 2010, the Court granted our motion declaring that DuPont and
Pioneer are not licensed to create a product containing ROUNDUP READY and Optimum® GAT® traits
stacked in combination. The remaining patent claims are set for trial on Sept. 12, 2011.
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2009, and Monsantos
report on Form 10-Q for the quarterly period ended Nov. 30, 2009, starting the week of March 7,
2004, a series of purported class action cases were filed in 14 different state courts against
Pioneer and us. The suits allege that we conspired with Pioneer to violate various state
competition and consumer protection laws by fixing and artificially inflating the prices and fees
for our various biotechnology traits and seeds containing those traits and imposing certain use
restrictions. All of these cases have been transferred to the U.S. District Court for the Eastern
District of Missouri and consolidated, except for one case that was pending in state court in
Tennessee, which has been dismissed. The Court set a Nov. 15, 2010, date for hearing to determine
class certification. Pioneer has entered a stipulated settlement agreement with individual
plaintiffs with no settlement class being certified.
Governmental Proceedings and Undertakings
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2009, we have reported
the accidental harvest of 0.22 acres of regulated Bt research cotton by a cooperator to the FDA,
EPA and USDA. The Bt protein present in this research cotton is nearly identical to the protein in
a corn product that has already obtained full approval in the United States and many foreign
markets. On May 20, 2009, the EPA granted a time-limited exemption from the requirement of a
tolerance for the protein in the research cotton, reaffirmed the safety of the protein in food and
feed, and provided notice to the USDA and FDA that the cottonseed may now enter U.S. domestic
commerce. On Feb. 10, 2010, we settled with the USDA, without admitting liability, and paid a civil
penalty of an immaterial amount.
52
|
|
|
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
As described in our Report on Form 10-K for the fiscal year ended Aug. 31, 2009, and Monsantos
report on Form 10-Q for the quarterly period ended Nov. 30, 2009, on Dec. 2, 2005, the Federal
Revenue Service of the Ministry of Finance of Brazil issued a tax assessment against our wholly
owned subsidiary, Monsanto do Brasil Ltda., challenging the tax treatment of $575 million of notes
issued in 1998 on the basis that the transactions involving the notes represented contributions to
the capital of Monsanto do Brasil rather than funding through issuance of notes. The assessment
denies tax deductions for approximately $1.1 billion (subject to currency exchange rates) of
interest expense and currency exchange losses that were claimed by Monsanto do Brasil under the
notes. The assessment seeks payment of approximately $230 million (subject to currency exchange
rates) of tax, penalties and interest related to the notes, and would preclude Monsanto do Brasil
from using a net operating loss carryforward of approximately $1 billion (subject to currency
exchange rates). The issuance of the notes was properly registered with the Central Bank of Brazil
and we believe that there is no basis in law for this tax assessment. On Dec. 29, 2005, Monsanto do
Brasil filed an appeal of this assessment with the Federal Revenue Service. On Oct. 28, 2008, the
company received a partially favorable decision issued by the first level of Administrative Court.
The Court reduced the assessed penalty from 150% to 75%, respectively, from $79 million to
$40 million (each subject to currency exchange rates) and maintained the tax and interest. On
Nov. 26, 2008, we filed an appeal before the second level of Administrative Court with regard to
the adverse portion of the decision by the first level of Administrative Court. The Federal Revenue
Service also appealed the portion of the decision favorable to Monsanto do Brasil. The company
continues to believe that there is no basis in law for this tax assessment. Under the terms of a
tax sharing agreement concluded with Pharmacia at the time of our separation from Pharmacia,
Pharmacia would be responsible for a portion of any liability incurred by virtue of the tax
assessment. As noted, certain dollar amounts have been calculated based on an exchange rate of
1.8 Brazilian reais per U.S. dollar, and will fluctuate with exchange rates in the future.
On Jan. 12, 2010, the Antitrust Division of the U.S. Department of Justice (DOJ) issued a civil
investigative demand to Monsanto requesting information on our soybean traits business. Among other
things, the DOJ has requested information regarding our plans for and licensing of soybean seed
containing ROUNDUP READY or ROUNDUP READY 2 YIELD traits. We are cooperating with this request.
ITEM 1A. RISK FACTORS
Please see Caution Regarding Forward-Looking Statements, at the beginning of this Report on Form
10-Q and Part I Item 1A of our Report on Form 10-K for the fiscal year ended Aug. 31, 2009, for
information regarding risk factors. There have been no material changes from the risk factors
previously disclosed in our Report on Form 10-K.
53
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
Issuer Purchases of Equity Securities
The following table is a summary of any purchases of equity securities during the second quarter of
fiscal year 2010 by Monsanto and any affiliated purchasers, pursuant to SEC rules.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(c) Total Number of Shares |
|
|
(d) Approximate Dollar |
|
|
|
|
|
|
|
(b) Average |
|
|
Purchased as Part of |
|
|
Value of Shares that May |
|
|
|
(a) Total Number of |
|
|
Price Paid |
|
|
Publicly Announced Plans |
|
|
Yet Be Purchased Under |
|
Period |
|
Shares Purchased |
|
|
per Share (1) |
|
|
or Programs |
|
|
the Plans or Programs |
|
|
December 2009: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dec. 1, 2009, through Dec. 31, 2009 |
|
|
106,725 |
(2) |
|
$ |
82.51 |
|
|
|
99,500 |
|
|
$ |
459,431,394 |
|
January 2010: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Jan. 1, 2010, through Jan. 31, 2010 |
|
|
539,919 |
(3) |
|
$ |
81.19 |
|
|
|
537,900 |
|
|
$ |
415,759,819 |
|
February 2010: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Feb. 1, 2010, through Feb. 28, 2010 |
|
|
107,300 |
|
|
$ |
76.64 |
|
|
|
107,300 |
|
|
$ |
407,536,762 |
|
|
Total |
|
|
753,944 |
|
|
$ |
80.73 |
|
|
|
744,700 |
|
|
$ |
407,536,762 |
|
|
|
|
|
(1) |
|
The average price paid per share is calculated on a trade date basis and excludes
commission. |
|
(2) |
|
Includes 7,225 shares withheld to cover the withholding taxes upon the vesting of
restricted stock. |
|
(3) |
|
Includes 2,019 shares withheld to cover the withholding taxes upon the vesting of
restricted stock. |
In April 2008, the board of directors authorized a repurchase program of up to $800 million of
the companys common stock over a three-year period. This repurchase program commenced Dec. 23,
2008, and will expire on Dec. 23, 2011. There were no other publicly announced plans outstanding as
of Feb. 28, 2010.
54
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
ITEM 5. OTHER INFORMATION
At our Annual Meeting of Shareowers on Jan. 26, 2010, three matters were submitted to a vote of
shareowers.
1. |
|
Frank V. AtLee III, David L. Chicoine, Ph.D., Arthur H. Harper, and Gwendolyn S. King were
nominated and elected to serve as directors until the 2013 Annual Meeting or until a successor
is elected and has qualified or until his or her earlier death, resignation or removal. Votes
were cast as follows: |
|
|
|
|
|
|
|
|
|
|
|
|
|
Name |
|
Votes For |
|
Votes Against |
|
Votes Abstain |
Frank V. AtLee III |
|
|
378,871,488 |
|
|
|
6,719,053 |
|
|
|
706,603 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
David L. Chicoine, Ph.D. |
|
|
383,332,051 |
|
|
|
2,477,729 |
|
|
|
487,365 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Arthur H. Harper |
|
|
383,219,811 |
|
|
|
2,577,067 |
|
|
|
500,267 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gwendolyn S. King |
|
|
380,512,130 |
|
|
|
5,262,362 |
|
|
|
522,653 |
|
2. |
|
The appointment by the Audit and Finance Committee of the Board of Directors of Deloitte &
Touche LLP as independent registered public accounting firm for the year 2010 was ratified by
a vote of the shareowners. The Board recommended a vote for the proposal. A total of
424,478,014 votes were cast in favor of ratification, 10,219,320 votes were cast against, and
1,258,728 votes were counted as abstentions. |
|
3. |
|
The performance goals under the Monsanto Company 2005 Long-Term Incentive Plan was ratified
by a vote of the shareowners. The Board recommended a vote for the proposal. A total of
370,316,730 votes were cast in favor of ratification, 14,856,012 votes were cast against, and
1,123,100 votes were counted as abstentions. |
ITEM 6. EXHIBITS
Exhibits: The list of exhibits in the Exhibit Index to this Report is incorporated herein by
reference.
55
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned thereunto duly authorized.
|
|
|
|
|
|
MONSANTO COMPANY
(Registrant)
|
|
|
By: |
/s/ NICOLE M. RINGENBERG
|
|
|
|
Nicole M. Ringenberg |
|
|
|
Vice President and Controller
(On behalf of the Registrant and as Principal Accounting Officer) |
|
|
Date: April 8, 2010
56
|
|
|
MONSANTO COMPANY
|
|
SECOND QUARTER 2010 FORM 10-Q |
|
EXHIBIT INDEX
These Exhibits are numbered in accordance with the Exhibit Table of Item 601 of Regulation S-K.
|
|
|
|
Exhibit |
|
|
No. |
|
Description |
|
2
|
|
Omitted |
|
|
|
3
|
|
Omitted |
|
|
|
4
|
|
Omitted |
|
|
|
11
|
|
Omitted see Note 18 of Notes to Consolidated Financial Statements Earnings Per Share. |
|
|
|
12
|
|
Computation of Ratio of Earnings to Fixed Charges. |
|
|
|
15
|
|
Omitted |
|
|
|
18
|
|
Omitted |
|
|
|
19
|
|
Omitted |
|
|
|
22
|
|
Omitted |
|
|
|
23
|
|
Omitted |
|
|
|
24
|
|
Omitted |
|
|
|
31.1
|
|
Rule 13a-14(a) Certification (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002,
executed by the Chief Executive Officer). |
|
|
|
31.2
|
|
Rule 13a-14(a) Certification (pursuant to Section 302 of the Sarbanes-Oxley Act of 2002,
executed by the Chief Financial Officer). |
|
|
|
32
|
|
Rule 13a-14(b) Certifications (pursuant to Section 906 of the Sarbanes-Oxley Act of 2002,
executed by the Chief Executive Officer and the Chief Financial Officer). |
|
|
|
101.INS
|
|
XBRL Instance Document. |
|
|
|
101.SCH
|
|
XBRL Taxonomy Extension Schema Document. |
|
|
|
101.CAL
|
|
XBRL Taxonomy Extension Calculation Linkbase Document. |
|
|
|
101.DEF
|
|
XBRL Taxonomy Extension Definition Linkbase Document. |
|
|
|
101.LAB
|
|
XBRL Taxonomy Extension Label Linkbase Document. |
|
|
|
101.PRE
|
|
XBRL Taxonomy Extension Presentation Linkbase Document. |
57